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1.1 The Oropouche Virus 
The Oropouche virus (OROV) is an emerging virus that causes a very severe and acute febrile 
dengue-like illness called the Oropouche fever. This RNA virus is responsible for multiple and 
massive epidemic outbreaks in South America involving hundreds of thousands of infected 
people (Vasconcelos et al. 2009). OROV is an arthropod-borne virus, which is transmitted from 
one person to the next by the biting midge, Culicoides paraensis. Despite its current relevance 
very little is known about the virulence factors of OROV. 
1.1.1 Epidemiology 
ORO fever has grown to become the second most common arthropod-borne viral disease in 
Brazil, surpassed only by dengue (Figueiredo 2007). The Oropouche virus (OROV) was first 
isolated in 1955 from a febrile forest worker in Trinidad (Anderson et al. 1961). Only shortly 
after its first isolation, in 1961, the first urban outbreak of ORO fever was reported in Belem, 
Brazil with approximately 11,000 infected persons (Pinheiro et al. 1981). Since then, the virus 
caused 30 large, explosive outbreaks in cities and villages across Brazil and in neighboring 
South American countries, with some of the outbreaks involving up to 110,000 infected 
persons. The last reported epidemic was in 2006 in Brazil’s Amazon region and was apparently 
limited by the cessation of rainfall (Vasconcelos et al. 2009). 
Although the OROV currently causes its epidemics every 1 to 7 years in South American 
countries (with reports from Brazil, Panama, Peru and Trinidad), it has to be noted that the 
OROV epidemics have been associated with deforestation, colonization, unplanned 
urbanization and climate change (Vasconcelos et al. 2001). The possibility therefore exists that 
the arthropod vector of OROV, Culicoides paraensis increases its area of circulation. A close 
relative to this OROV vector, Culicoides imicola, which transmits the Bluetongue virus (family 
Reoviridae, genus Orbivirus) has already, for the first time, spread to northern Europe due to 
climate change and an increase in temperature (Elliott 2009). It is therefore probable that the 
OROV eventually confronts Middle and North America with epidemic outbursts of the ORO 
fever. Studies by the Tropical Medicine Foundation of Amazonas State have even shown a 
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constantly increasing area of circulation of the OROV and they have noted an increasing 
epidemic potential of the sickness (Mourãão et al. 2009).  
1.1.2 Clinical Aspects 
  Symptoms 1.1.2.1
The Oropouche virus causes the Oropouche fever. An Oropouche infection manifests itself in 
the form of an acute febrile episode, which can be very debilitating. This episode is 
accompanied by headache (99.1 %), chills (59.3 %), muscle pain (46.9 %), dizziness (39.8 %), 
photophobia (38.1 %), nausea/vomiting (36.3 %), and joint pain (21.2 %) (Vasconcelos et al. 
2009). 
These symptoms usually reoccur a few days after the first febrile episode; they are then 
however less severe. Some patients also develop aseptic meningitis. Patients however usually 
fully recover without any apparent after effects, even in most serious cases. The incubation 
period of the virus ranges from four to eight days. Most infections are symptomatic with a 
ratio of symptomatic to asymptomatic of 2:1 (Pinheiro et al. 1982). Diagnosis of the 
Oropouche fever occurs mainly serologically (Saeed et al. 2001) 
 Therapy 1.1.2.2
Currently, there is no causal therapy. Only symptomatic interventions such as oral analgesic 
and anti-inflammatory agents are used. The OROV is resistant against the nucleoside analog 
Ribavirin (Livonesi et al. 2006). OROV is insensitive to IFN after infection is established 




The OROV belongs to the Simbu serogroup of the genus Orthobunyavirus, which is one of the 
five genera within the Bunyaviridae family.  
The large virus family Bunyaviridae is one of the most extensive virus families with over 350 
members. All of its members are RNA viruses that have a tri-segmented, single stranded 
genome of negative polarity. The members of this family are divided into 5 genera based on 
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their serological and biochemical properties. Four of the five genera, namely the Orthobunya-, 
Phlebo-, Nairo-, and the Hantavirus, contain vertebrate-infecting viruses, whereas the genus 
Tospovirus contains only plant-infecting viruses. Irrespective of their serological and 
biochemical similarities, the bunyaviruses show diversity in terms of their hosts and vectors, 
and in their genome coding and replication strategies (Elliott 1997). With relevance to this 
thesis, the relationship between the Oropouche virus and the La Crosse, Rift Valley fever and 
Bunyamwera virus should be noted.  
 
 





California virus La Crosse virus 
(= encephalitis) 
  







 Bunyamwera virus  
Phlebovirus Phlebotomus 
fever virus 
Rift Valley fever virus 
(= encephalitis) 
Rift Valley fever 
virus 
 
Nairovirus CCHF* virus CCHF* virus 
(= hemorrhagic fever) 
CCHF* virus  
Hantavirus Hantaanvirus Hantaanvirus 
(= hemorrhagic fever) 
  
Tospovirus    Tomato-Spotted-Wilt 
virus 
 
Table 1:  The five genera of the Bunyaviridae family. Examples of pathogenic viruses, the sicknesses they 
cause in humans and their preferred host species are stated under every serogroup. The genus 
Orthobunyavirus has three serogroups. * = Crimean Congo hemorrhagic fever 
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 Structure and Genome 1.1.3.1
The Oropouche virus is an enveloped virus of approximately 100 nm in diameter. Just like the 
other members of the Bunyaviridae family, the Oropouche virus has a tri-segmented, single-
stranded RNA genome (Elliott and Weber 2009).  
The largest segment of the OROV genome is called the L-, the medium-sized segment the M- 
and the smallest segment the S segment. All of these RNA segments are of negative polarity. 
Each of the segments is encapsidated with viral nucleocapsid proteins. This encapsidation 
forms the ribonucleocapsid (RNP) complex and it is solely this complex that serves as the 
template for the viral polymerase during transcription and replication (Elliott 1997).  
The three genome segments encode four structural proteins that make up the viral particle 
and two Non-structural proteins, one of which (NSs protein) is known to be a major virulence 
factor of Orthobunya- and Phleboviruses amongst the Bunyaviridae.  
The L (large) RNA segment encodes the L protein, the RNA-dependent RNA polymerase 
(approx. 248 kD; 2250 amino acids; BeAn19991 strain). OROV has to take along this 
polymerase in its viral particles because of its encoding strategy, which requires the 
transcription of its negative sense RNA into positive sense RNA. Approximately 25 copies of 
the L protein are associated with the ribonucleocapsid complex of every virus particle (Aquino 
et al. 2003).  
The M (medium) segment encodes the viral surface proteins, glycoprotein Gn (approx. 103 kD; 
939 amino acids) and Gc (approx. 32 kD; 290 amino acids), which project from the virus’ 
surface by approximately 10 nm and are involved in the attachment of the virus to the host 
cell. In between both the Gn and the Gc genes, is the NSm gene which produces the 19 kD 
(175 amino acid) NSm protein . Little is known about this protein. The molecular masses are 
calculated based on the amino acid sequence of the OROV prototype strain TRVL 9760 (Wang 
et al. 2001). 
The S (small), 754-nucleotide segment encodes the 231-amino acid structural nucleoprotein, 
also known as the N-protein. There are approximately 2100 N-protein units per complete virus 
particle and they encapsidate each of the genome RNA segments. The N-gene contains 
another gene, which encodes a smaller 91-amino acid non-structural protein, the NSs protein. 
The NSs open reading frame exhibits a +1 frameshift with respect to the N open reading 
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frame. Therefore translation of the S segment transcript leads to the production of both N and 
NSs protein by alternative initiation of translation at the AUG codons of the open reading 
frames of N and NSs (Elliott and McGregor 1989), (see Figure 2). The nucleotide and amino 
acid numbers of the S segment refer to those of the prototype OROV strain, TRVL 9760, 
isolated in Trinidad (Saeed et al. 2000). 
Phylogenetic analysis of the different OROV strains showed that three genotypes could be 
distinguished. To genotype I belong the prototype strain from Trinidad and most of the strains 
isolated in Brazil, genotype II contains the six Peruvian strains that were isolated between 
1992 and 1998, and two strains isolated from western Brazil in 1991. Genotype III contains 
four strains isolated in 1989 in Panama (Saeed et al. 2000). A new, fourth genotype has also 
recently been described which include Brazilian strains from the Amazonas state (Vasconcelos 
et al. 2011) 
 
 
                            
 Figure 1. The prototype structure of the Bunyaviridae with their tri-segmented genome. The 
genomic RNA segments are encapsidated with the nucleoprotein. The figure also shows the 






                 




 Transcription and Replication 1.1.3.2
The entire replication cycle of the Bunyaviridae has not yet been fully understood. However, it 
is known that the OROV adheres to an unknown receptor on the surface of host cells using its 
glycoproteins, Gn and Gc. The OROV particles are taken up by receptor-mediated endocytosis. 
After uncoating by low pH-dependent membrane fusion and entry into the cytoplasm, the 
viral polymerase (L-protein, a RNA-dependent RNA polymerase) starts transcription of the 
genomic negative sense RNA (Elliott and Weber 2009). 
Firstly, the L protein, which has an endonuclease enzyme property, cuts off a few nucleotides 
including the cap structure at the 5’ end of cellular mRNAs present in the cytoplasm (cap-
snatching). The L protein then uses these oligonucleotides as its primer, pairing it to each of 
the three viral genome segments. The L protein then begins attaching nucleotides to the 
primer, producing viral mRNA which contains 12 to 18 nucleotides of cellular origin and which 
is capped at its 5’ end. The viral mRNA synthesis then terminates at 50 to 150 nt before the 
end of the genomic template. The 3’ end is not polyadenylated (Elliott and Weber 2009). 
This naked viral mRNA is then translated by cellular ribosomes. Once the N (nucleocapsid) 
protein has reached a critical level, it interacts with the L protein and the RNA synthesis 
switches to replication mode. This time, RNA synthesis is primer-independent and a full-
length, exact complementary copy of the genome in positive sense orientation is produced 
(the antigenome). During synthesis of this antigenome, it is encapsidated by the pool of N 
proteins prepared beforehand. The resulting ribonucleocapsid complex serves as a template 
for the synthesis of progeny negative-sense genomes that are also encapsidated (Elliott and 
Weber 2009). 
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Assembly of the viral glycoproteins and the ribonucleocapsid complexes as wells as budding of 
virions takes place in the Golgi apparatus of the host cell which leads to the release of viral 
progeny from the infected host cell.  
 
 
1.2 The Innate Immune Response to Viruses: Type I Interferons 
1.2.1 Interferon Types and their Molecular Properties 
IFN proteins are commonly grouped into three types based on their unique, respective 
receptors and their different roles in immune processes. The type I Interferons are also called 
the viral IFNs and consist of IFN-α, IFN-β  and IFN-ω, -ε , -τ, -δ and -κ. Type II IFN is also known 
as the immune IFN (IFN-γ) and is involved in allergic response, in tumor control and in host 
defense against intracellular pathogens (Weerd and Nguyen 2012). The type III IFNs have only 
been recently described and comprise IFN-γ1, -γ2 and -γ3 (Kotenko et al. 2002).  
Type I and type III IFNs are induced by viral infection and type II IFN by mitogenic and antigenic 
stimuli. Most cell types are able to produce Type I IFNs in response to viruses. Only a few 
special cells are able to produce type II IFN, such as activated Natural Killer cells, CD4 Th1 cells 
and CD8 cytotoxic suppressor cells (Bach et al. 1997).  
The type I interferon system constitutes a very powerful first line of defense against viral 
infections (Randall and Goodbourn 2008). IFN-α and -β genes are promptly induced in a cell in 
response to viral infection. These IFNs activate a signal-transduction pathway that trigger the 
transcription of a diverse set of genes that, in total, establish an antiviral response in the 
infected cell itself and in neighboring ones. The efficiency with which a virus can antagonize 
this cellular IFN system is an important factor of its pathogenicity. Recent research carried out 
by the Virology Institute, Göttingen (Keisers) showed that cells infected with the Oropouche 
virus are prevented from producing sufficient IFN amounts. 
Humans have a large number of type I IFN genes: 14 IFN-α genes, 1 IFN-β and 1 IFN-ω gene 
(Pestka et al. 2004) They all lack introns and are clustered on the short arm of chromosome 9. 
The IFN-α genes  have been studied in mice and, based on these studies, can be divided into 
two groups: the immediate-early response gene, IFN-α4, which is expressed very quickly and 
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the second group of IFN-α genes which are expressed much more slowly. IFN-α gene products 
seem to function as monomers and IFN-β and IFN-γ as homodimers (Bach et al. 1997). IFN-β 
was the first of the IFNs to be purified and characterized. It is best understood. IFN-β has a 
wide range of important biological effects on the human immune system (Huber and Farrar 
2011).  
 
1.2.2 Interferon Induction 
Type I IFNs are produced and secreted by cells in response to viral infection, long before the 
adaptive immune system can produce specific antibodies. These IFNs (-α/-β) activate a 
number of so-called IFN-stimulated genes (ISG) in the infected cell as well as in uninfected 
surrounding cells. A number of these expressed ISGs produce proteins that directly or 
indirectly antagonize viral multiplication. Three phases of the interferon system can be 
distinguished. Firstly, the host cell has to recognize the virus and start its intracellular signaling 
processes that lead to the transcription and translation of the IFN genes (IFN induction). 
Secondly, the secreted IFNs initiate a signaling cascade, which leads to the expression of 
antiviral proteins (IFN signaling), and lastly, the synthesized IFN-induced antiviral proteins 
establish an antiviral state. 
 
Recognition: Four major pattern recognition receptor families are known to play a big role in 
host cells recognition of invading pathogens: Toll-like receptors (TLRs), cytosolic RIG-I-like 
receptors (RLR), Nod-like receptors and C-type lectins.  
TLRs are expressed in cells of the specific immune system. They are found on the cell surface 
as well as on the membranes of some intracellular organelles, which are normally (in a non-
infected state) free of RNA.  The binding of certain non-self ssRNA (TLR7, TLR8), dsRNA (TLR3) 
and CpG DNA (TLR9) to these receptors trigger certain recognition pathways that 
subsequently lead to the acquisition of an antiviral state (Kawai and Akira 2010).  
The two Nod-like receptor family members Nod1 (Chamaillard et al. 2003) and Nod2 (Girardin 
et al. 2003) have been identified to play more of a role in the recognition of the intracellular 
bacterial components that are produced during degradation or synthesis of bacterial 
peptidoglycan.  
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As TLRs are expressed only in specific immune cells, they cannot account for the anti-viral 
reaction, for example, in epithelial cells. Cytosolic RLRs and Nod-like receptors that are 
expressed in most cell types are responsible for the anti-viral reaction in other invaded cells. 
The detection of cytoplasmic viral RNA is largely carried out by RLR family members such as 
MDA5 and RIG-I. They recognize so-called PAMPs, which are conserved pathogen-associated 
molecular patterns. The binding of viral RNA to RIG-I/MDA5 starts complex pathways that end 
in the activation of the three distinct transcriptional factors IRF-3, the heterodimers NF-κB and 
ATF-2/c-Jun (AP-1) that are required for the production of IFN and inflammatory cytokines 
(Hornung et al. 2006, Kato et al. 2011). RIG-I has the ability to bind to the uncapped 5’ 
triphosphorylated RNA end of a single stranded viral genome, as does another intracellular 
protein called PKR (Hornung et al. 2006). This cellular recognition is practical, because many 
viruses cannot cap their own RNA, as human cells do. In addition to the capping of RNA, 
human cells distinguish self from non-self RNA by methylating the ribose sugar molecule at 
position 2’-O at the 5’-end of the mRNA. MDA5 recognizes this and is activated by viral RNA 
that lacks this cell-typical signature (Züst et al. 2011).  
Once the C-terminal RNA helicase domain of RIG-I and MDA5 have come into contact with 
viral RNA, the RLRs undergo a conformational change. This change allows them to associate 
with the adaptor protein MAVS located on the outer mitochondrion membrane. This complex 
is responsible for the downstream activation NF-κB and IRF-3/IRF-7. 
The activated RIG-I/MDA5 and MAVS adaptor protein activate TBK1 and IKKε that together 
with the aid of the protein TRAF3 phosphorylate IRF-3 and IRF-7 that are constitutively present 
in the host cells cytosol (Fitzgerald et al. 2003). Phosphorylated IRF-3 either homodimerizes or 
heterodimerizes with IRF-7 and translocates to the cell nucleus where it serves as a 
transcriptional factor (Honda et al. 2006). 
NF-κB is permanently bound to inhibiting proteins in the cytosol of unstimulated cells called 
IκB. This inhibiting protein prevents the nuclear translocation of the transcription factor NF-κB. 
The complex of activated RIG-I/MDA5, the MAVS adaptor protein together with the IKK family 
members TBK1 and IKKε however phosphorylate this inhibiting protein. Phosphorylated IκB 
dissociates itself from NF-κB, is marked with ubiquitin and it is subsequently proteolytically 
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degraded (Karin and Ben-Neriah 2000). In contrast to IRF-3/-7 activation TRAF6 is the required 
protein (Fitzgerald et al. 2003).  
ATF-2/c-Jun (AP-1) is also activated during viral infection by a complex cascade of reactions 
(Du et al. 1993). 
 
IFN-β gene transcription and translation is initiated, when the transcription factors AP-1, NF-
κB and IRF-3, all of which are activated by viral infections, bind to the nucleosome-free (open) 
enhancer of the IFN-β gene which is -107 to -47 bp upstream of the transcriptional starting 
point (Panne et al. 2007). All three factors have to interact with each other and the enhancer 
region for the IFN-β gene to be transcribed (Maniatis et al. 1998). IRF-3 is constitutively 
expressed in cells. Upon viral infection, the signaling processes result in the phosphorylation of 
its C-terminal regulatory domain, permitting its homodimerization and translocation to the 
cell nucleus, where it binds to CBP/p300 (Takahasi et al. 2010). This enables the 
phosphorylated IRF-3 to bind to the IFN-β enhanceosome. Of the three transcriptional factors 
activated upon viral infection, IRF-3 appears to be the most important. It alone has the ability 
to induce the IFN-β gene expression in the absence of the other two transcriptional factors, 
provided its concentration is high enough (Hiscott et al. 1999). 
Two nucleosomes cover the TATA-box and the transcription start site of the IFN- β gene. 
Enzymes first have to acetylate the histones in the nucleosome, which then move away and 
give general transcription factors like the TATA-box binding protein access to the region 
(Lomvardas and Thanos 2001). The enhanceosome (enhancer + IRF-3/7 + NF-κB + AP-1) then 
recruits the RNA polymerase II and activates IFN-β mRNA synthesis (Panne et al. 2007). The 




 Figure 3. Overview of interferon induction and interferon effects. Three critical transcription factors, IRF-3, 
NF-B and AP1 (ATF-2/cJun) are activated after viral recognition and they bind to the enhancer of the IFN- 
gene, enabling its expression. (Figure from Dr. rer. nat. M. Spiegel, Virology Institute, Göttingen) 
 
1.2.3 Interferon Signaling 
The different IFN-α/–β subtypes all bind to a common type I IFN receptor (IFNAR). These 
receptors are ubiquitously and constitutively expressed (de Weerd et al. 2007). All the studied 
IFN-α and –β isoforms bind to this IFNAR, however with different affinities. IFNAR is composed 
of two type I heterodimeric, transmembrane subunits, called IFNAR-1 and IFNAR-2. The janus 
kinases JAK-1 and TYK-2 are permanently associated with the IFNAR. The N-terminus of signal 
transducer and activator of transcription 2, shortly called STAT 2, associates itself with the 
cytoplasmic part of IFNAR-2, before cytokine activation. Upon IFN binding the two IFNAR 
subunits co-ligate and activate the JAK-STAT signaling pathway: JAK proteins phosphorylate 
the tyrosine residues within the cytoplasmic domain of IFNAR1/-2 and in the cytoplasmic 
STAT-2 protein, which is associated with IFNAR-2. Phosphorylated STAT-2 recruits STAT-1 from 
the cytoplasm to form a heterodimer. Phosphorylated STAT-1 and STAT-2 associate with 
another protein called IRF-9. . This complex is now called the interferon-stimulated gene 
factor-3, ISGF-3. This ISGF-3 activates the majority of the interferon-stimulated genes, ISGs, 
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after translocation to the cell nucleus where it binds to the interferon-stimulated response 
elements (ISRE) found in the promoters of ISGs (Huber and Farrar 2011, Schindler et al. 2007), 
see Figure 3. 
Over 300 ISGs exist that have antiviral, antiproliferative, and immunomodulatory functions. 
These include enzymes, diverse transcription factors, surface glycoproteins, cytokines, 
chemokines and others with unknown function. IRF-7 is an example of one of the transcription 
factors produced that is capable of activating many other members of the IFN gene family. Its 
production increases the cascade reactions once viral products have been recognized by the 
cell. Once IRF-7 is phosphorylated in infected cells, it becomes active (Marie et al. 1998). The 
major known proteins with direct antiviral activity are the Mx GTPases, PKR and the 
oligoadenylate synthetases. Mx GTPases target viral nucleocapsids, thereby inhibiting RNA 
synthesis. PKR that is activated by dsRNA and phosphorylates the cellular initiation factor eIF-
2α, thereby inhibiting translation of both viral and cellular mRNAs. The oligoadenylate 
synthetases activate the RNase L in the cytoplasm, which then degrades RNA in the cytoplasm 
(Samuel 2001).  
Furthermore, type I IFN induces in a positive feedback loop Nod2 (Kim et al. 2011) and RIG-1 
(Hu et al. 2011). This increases immune surveillance in the local microenvironment 
establishing a higher cellular resistance to infection. 
Type I IFN bridges the gap between the innate (which mainly produces it) and the adaptive 
immune system. Plasmacytoid dendritic cells produce large amounts of type I IFN. Apart from 
its function in the innate immune system, type I IFN activates CD8⁺ T cells and supports cross-
presentation. Likewise type I IFN promotes the differentiation of CD4⁺ T-cells into T helper 
cells type 1 (Th1), whereas the differentiation into Th2 and Th17 is restricted (Huber and 
Farrar 2011). IFN-β also up-regulates MHC type I molecules on the dendritic cell membrane 
(Inácio et al. 2012); it promotes dendritic cell maturation (Santini et al. 2000) and activation 




1.2.4 Bunyaviridae counter-actions to Interferon 
Bunyaviruses possess a tri-segmented genome, which means that a viral particle has three 
putative RIG-1-activating 5’ triphosphate ends in its ssRNA genome. To counterbalance this, 
Orthobunyaviruses produce a very potent antagonist of the IFN system, the so-called NSs 
protein (Weber et al. 2002). The so far characterized NSs proteins of the Orthobunyaviruses 
Bunyamwera (Thomas et al. 2004) and La Crosse (Blakqori et al. 2007) and of the Phlebovirus 
RVFV (Billecocq et al. 2004) that have been studied until now are known to inhibit RNA 
polymerase II-mediated cellular transcription thereby preventing IFN synthesis. These 
respective NSs proteins however all have a different inhibition mechanism. 
 
1.3 Aim of the study 
This thesis aims on the one hand at characterizing Oropouche virus’ major virulence factor, 
the so-called Non-structural (NSs) protein. On the other hand, it aims at setting up a 
minireplicon system for the Oropouche virus that will eventually allow for the targeted 
manipulation of its genome, permitting an insight into the viruses’ replication and 
transcription processes, and shedding some light on virus-host cell interactions. 
Understanding these processes could pave the way for developing therapeutic interventions 
against this currently untreatable disease. 
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
The following is a list of the chemicals that were used during experimental work with their 
respective acquisition companies. 
Chemicals Company 
10 x Transcription buffer Roche Diagnostics GmbH, Mannheim, Germany 
Ammonium acetate  
Distilled Water for PCR (DNase-/RNase-free) Invitrogen Corporation, Carlsbad, California, U. S. A. 
Dithiothreitol (DTT) Serva GmbH, Heidelberg, Germany 
Dulbecco’s PBS [10X] c.c.pro GmbH, Oberdorla, Germany 
Ethanol  Carl Roth, Karlsruhe, Germany 
FCS c.c.pro GmbH, Oberdorla, Germany 
FluorSave™ Reagent Calbiochem, San Diego, California, U. S. A. 
Isopropanol Merck KgaA, Darmstadt, Germany 
L-Glutamin [200 mM] c.c.pro GmbH, Oberdorla, Germany 
Paraformaldehyde Sigma, Munich, Germany 
Passive Lysis Buffer [5x] Promega Corporation, WI, U. S. A. 
Purified Bovine Serum Albumin (BSA) [10 
mg/ml] 
New England BioLabs Inc., Ipswich, MA, U. S. A. 
Random-Hexamer-Primer GE Healthcare, Freiburg, Germany 
Triton X-100 Serva GmbH, Heidelberg, Germany 
Trypan Blue (0.4 %) Sigma-Aldrich, St. Louis, U. S. A. 
 
2.1.2 Buffers and Solutions 
The following is a list of the buffers and solutions that were used during experimental work 
and their composition. 
Buffers and Solutions Constitution 
0.5% Triton X-100 250 µl in 50 ml 1 x PBS 
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1 % FCS/PBS 1 µl FCS in 99 µl 1 x PBS 
1 x PLB  10 µl PLB [5 x] in 40 µl distilled water 
3 % Para formaldehyde 3 g Paraformaldehyde in PBS 
BSA [1 mg/ml] 10 µl BSA [10 mg/ml] in 90 µl distilled water 
Dulbecco’s PBS [10X] 2 g KCl, 2 g KH2PO4, 80 g NaCl, 5,76 g N2HPO4, ad 1 l 
H2O 
Dulbecco’s PBS [1X] 100 ml PBS [10X] ad 900 ml H2O 
DMEM  500 ml DMEM, 50 ml FCS, 100 U/ml Penicillin, 100 
µg/ml Streptomycin, and 526,6 mg/l L-Glutamin 
LB-Agar with Ampicillin 10 g Bacto Tryptone, 5 g Bacto Yeast Extract, 10 g 
NaCl, 1 ml Ampicillin [100 µg/ml], 15 g Bacto Agar, 
ad 1 l H2O 
LB-Medium with Ampicillin 10 g Bacto Tryptone, 5 g Bacto Yeast Extract, 10 g 
NaCl, 1 ml Ampicillin [100 µg/ml], ad 1 l H2O 
 
2.1.3 Kits and Sets 
The following is a list of the kits and sets that were used during experimental work with their 
respective acquisition companies. 
Kits and Sets Company 
DNA-free Ambion Inc., Texas, U. S. A. 
Dual-Luciferase Reporter Assay  Promega Corporation, Madison, U. S. A. 
FuGENE 6 Transfection Reagent Roche Diagnostics GmbH, Mannheim, Germany 
Lipofectamine Transfection Reagent 2000 Invitrogen Corporation, Carlsbad, California, U. S. A. 
NucleoBond PC100 Plasmid Purification  Macherey-Nagel GmbH & Co. KG, Düren, Germany 
Quant-iT RiboGreen RNA Assay  Invitrogen Corporation, Carlsbad, California, U. S. A. 
rNTP Set [Each 20 µmol] Roche Diagnostics GmbH, Germany 
RNA Cap Structure Analog (7mG(5’)ppp(5’)G 
Sodium salt) 
New England BioLabs Inc., Ipswich, MA, U. S. A. 
Transmesenger Transfection Reagent  QIAGEN GmbH, Hilden, Germany 
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2.1.4 Antibiotics 
The following is a list of the antibiotics that were used during experimental work with their 
respective acquisition companies. 
Antibiotics Company 
Ampicillin  Serva, Heidelberg, Germany 
G418 (Geneticin) c.c.pro GmbH, Oberdorla, Germany 
Penicillin Streptomycin (PS) c.c.pro GmbH, Oberdorla, Germany 
 
2.1.5 Cell lines 
The following are the cell lines that were used. Their respective origins, source and culture 
media are also stated. 
Cell lines Origin tissue (Organism) Acquired from Culture medium 
293  Embryonal  
kidney (Human) 
Microbix  
Biosystems Incorporated,  
Ontario, Canada 
DMEM supplemented with 
10 % FCS  
BSR-T7 Kidney (Hamster) Prof. Dr. K. Conzelmann, 
Ludwig-Maximilians-
University, Munich, Germany 
DMEM supplemented with 
10 % FCS + G418 (120 µl in 
12 ml DMEM) 
Vero E6 Kidney  
epithelium  
(African green monkey) 
Gerhard Dobler Microbiology 
Institute of the Armed Forces, 
Munich, Germany 
DMEM supplemented with 
10 % FCS 
 
2.1.6 Bacteria 
The following are the Bacteria that were used during experimental work with their respective 
acquisition companies.  
Bacteria Genotype Company 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)]c 
Stratagene, Santa Clara, 
California, U. S. A. 
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2.1.7 Media 
The following is the list of the media that were used during experimental work with their 
respective acquisition companies. 
Media Company 
DMEM c.c.pro GmbH, Oberdorla, Germany 
Opti-MEM I Medium Invitrogen Corporation, Carlsbad, California, U. S. A. 
 
2.1.8 Plasmids 
The following is a list of the plasmids that were used, their respective description and their 
source. Every listed plasmid has an ampicillin resistance gene. This ampicillin resistance is for 
selecting the E. coli that have incorporated the plasmids during transformation (see 2.2.3 
Transformation of Plasmid-DNA).  
Plasmids Description Source 
p125-luc The firefly luciferase gene expression of this 
plasmid correlates with the IFN-β promoter 
activation 
Takashi Fujita, The Tokyo 
Metropolitan Institute of 
Medical Sciences, Tokyo, 
Japan 
p55A2-luc This reporter plasmid is controlled by a NF-
κB-responsive promoter and expresses 
firefly luciferase 
Takashi Fujita, The Tokyo 
Metropolitan Institute of 
Medical Sciences, Tokyo, 
Japan 
p55C1B-luc This reporter plasmid is controlled by an IRF-
3-responsive promoter and expresses firefly 
luciferase 
Takashi Fujita, The Tokyo 
Metropolitan Institute of 
Medical Sciences, Tokyo, 
Japan 
pAP-1-luc This 5.7 kb reporter plasmid is controlled by 
an AP-1-responsive  promoter and expresses 
firefly luciferase 
Stratagene, Santa Clara, 
California, U. S. A. 
pFC-MEKK Controlled by the constitutively active CMV-
Promoter, expressing MEKK  
Stratagene, Santa Clara, 
California, U. S. A. 
pGL3-FF-luc Control plasmid for the expression of firefly Promega, Mannheim, 
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luciferase under the control of the 
constitutively active SV40 promoter 
Germany 
pI.18 Empty eukaryotic expression vector. Carries 
the  constitutively active hCMV IE-promoter 
and the hCMV intron A followed by a 
multiple cloning site for the insertion of 
cDNA and a hCMV polyA signal  
Jim Robertson, National 
Institute for Biological 
Standards and Control, 
Hertfordshire, United 
Kingdom 
pI.18-FLAG-ΔMx Expression plasmid for N-terminal FLAG-
tagged and truncated Mx protein 
Prof. Dr. Friedemann Weber, 
Universitätsklinikum, Freiburg, 
Germany  
pI.18-OROV-NSs-Flag Expression plasmid for C-terminal FLAG 
tagged NSs of OROV 
Virology Institute, Göttingen, 
Germany 
pI.18-RNSs-ZF5 Expression plasmid for C-terminal FLAG 
tagged NSs of RVFV strain ZH548 




Expression plasmid NSs of RVFV strain clone 
13 
Virology Institute, Göttingen, 
Germany 
pI.18-RVFV-NSs-Z1 Expression plasmid NSs of RVFV strain ZH548 Virology Institute, Göttingen, 
Germany 
pIRF-3(5D) Expression plasmid for a constitutively active 
phosphomimetic form of IRF-3 
John Hiscott,  
McGill University, 
Montreal, Canada 
pRL-SV40 Expression plasmid for renilla luciferase 
Expression is driven by the constitutively 





This LACV minigenome plasmid has a T7 
polymerase promoter and contains the 
renilla luciferase gene in genomic 
orientation. The 3’ and 5’ ends are from 
NTRs of the LACV M segment in genomic 
orientation 





This OROV minigenome plasmid has a T7 
polymerase promoter and contains the 
renilla luciferase gene in antigenomic 
Virology Institute, Göttingen, 
Germany 
Material and Methods 19 
orientation. The 3’ and 5’ ends are from 




This OROV minigenome plasmid has a T7 
polymerase promoter and contains the 
renilla luciferase gene in genomic 
orientation. The 3’ and 5’ ends are from 
NTRs of the OROV M segment in genomic 
orientation 
Virology Institute, Göttingen, 
Germany 
pTM1-FFLuc This reporter plasmid has a T7 polymerase 
promoter and an EMCV-IRES followed by the 
firefly luciferase cDNA and the T7 terminator  
Prof. Dr. Friedemann Weber, 
Universitätsklinikum, Freiburg, 
Germany 
pTM1-OROV-cL This constitutively active plasmid is 
controlled by a T7 polymerase promoter and 
expresses the OROV L protein 
Virology Institute, Göttingen, 
Germany 
pTM1-OROV-cSmut This constitutively active plasmid is 
controlled by a T7 polymerase promoter and 
expresses the OROV N protein. The NSs 
protein is mutated to a dysfunctional form 
Virology Institute, Göttingen, 
Germany 
pTM1-LACV-L This constitutively active plasmid is 
controlled by a T7 polymerase promoter and 
expresses the LACV L protein 
Prof. Dr. Friedemann Weber, 
Universitätsklinikum, Freiburg, 
Germany 
pTM1-LACV-N This constitutively active plasmid is 
controlled by a T7 polymerase promoter and 
expresses the LACV N protein 
Prof. Dr. Friedemann Weber, 
Universitätsklinikum, Freiburg, 
Germany 
pUC19 pUC19 is a standard high-copy cloning vector 
for E. coli recombinants. 
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2.1.9 Primary Antibodies 
The following are the primary antibodies that were used.  
Primary Antibodies Description Target Company 
ANTI-FLAG Polyclonal Polyclonal rabbit  
IgG antibody 
DYKDDDDK sequence 
in fusion proteins  
Sigma-Aldrich, St. Louis, 




antibody, isolated from 
murine ascites fluid 
DYKDDDDK sequence 
in fusion proteins 
Sigma-Aldrich, St. Louis, 
Missouri, U. S. A. 
Pol II (N-20) Polyclonal rabbit  
IgG antibody 
N-terminus of RNA 
polymerase II 
Santa Cruz  
Biotechnology Inc., 
Dallas, Texas, U. S. A. 
RNA polymerase II H14 
antibody 
Monoclonal  
IgM antibody  
from murine ascites 
Phospho-serine 5  
in the heptapeptide 
repeat of the C-
terminal domain of 
the RNA polymerase II 
Covance,  
San Diego, California,  
U. S. A. 
RNA polymerase II H5 
antibody 
Monoclonal IgM 
antibody from murine 
ascites 
Phospho-serine 2 in 
the heptapeptide 
repeat of the C-
terminal domain of 
the RNA polymerase II 
Covance,  
San Diego, California,  
U. S. A. 
 
2.1.10  Secondary Antibodies 
The following are the secondary antibodies that were used.  
Secondary Antibodies Description Target   Company 
Cy 3-conjugated Anti-mouse 
antibody 
IgG Anti-mouse antibody 
developed in Donkey 







IgG Anti-rabbit antibody 
developed in Goat  
Fc part of rabbit 
antibodies 
Sigma, St. Louis, 
U. S. A. 
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2.1.11 Proteins, Enzymes, and Enzyme Inhibitors 
The following is a list of the proteins, enzymes and the enzyme inhibitors that were used with 
their respective acquisition companies. 
Enzymes, Protein Inhibitors and Other Proteins Company 
Tumor Necrosis Factor Alpha Sigma, St. Louis, U. S. A. 
T7 RNA polymerase [20 U/µl] Roche Diagnostics GmbH, Mannheim, Germany 
Trypsin/EDTA Solution Biochrom AG, Berlin, Germany 
rRNasin RNase Inhibitor [40 U/µl] Promega, Mannheim, Germany 
RiboLock RNase Inhibitor Fermemtas GmbH, St. Leon-Rot, Germany 
 
2.1.12  Devices and Equipment 
The following is a list of the devices and the equipment that were used with their respective 
acquisition companies 
Devices and Equipment Company 
Autoklav Typ Tecnoclav 50 Tecnomara, Zürich, Switzerland 
Bacteria Incubator Haraeus Instruments GmbH, Hannover, Germany 
Basic Glass Utilities Schütt, Göttingen, Germany 
Big pipette tips  (2 ml, 5 ml, 10 ml, 25 ml) Hirschmann Laborgeräte GmbH & Co. KG, Eberstadt, 
Germany 
Cell counting chamber Hycor Biomedical Inc., California, U. S. A. 
Cell culture flasks with filter (75 cm2, 25 cm2) Greiner Bio-One GmbH, Frickenhausen, Germany 
Cell culture plates (6 well, 12 well) Greiner Bio-One GmbH, Frickenhausen, Germany 
Centrifuge Eppendorf AG, Hamburg, Germany 
Centrifuge (Megafuge 1.0R) Thermo Scientific, Rockford, U. S. A. 
Chemidoc XRS System Bio Rad Laboratories GmbH, Munich, Germany 
Falcon tubes (15 ml, 50 ml) Sarstedt AG & Co, Nümbrecht, Germany 
Filter paper Whatman GmbH, Dassel, Germany 
FLUOstar OPTIMA Reader BMG LABTECH GmbH, Offenburg, Germany 
FLUOTRAC 600 96-well plate Greiner Bio-One GmbH, Frickenhausen, Germany 
Freezer (-140°C) Thermo Scientific, Rockford, U. S. A. 
Freezer (-20 °C) Liebherr GmbH, Ochsenhausen, Germany 
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Freezer (-80 °C) Thermo Scientific, Rockford, U. S. A. 
Fridge (5°C) Liebherr GmbH, Ochsenhausen, Germany 
Gel electrophoresis apparatus  Invitrogen Corporation, Carlsbad, California, U. S. A. 
Ice machine Ziegra, Isernhagen, Germany 
Incubator Heraeus Sepatech GmbH, Osterode, Germany 
Incubator bath Köttermann GmbH & Co KG, Uetze/Hänigsen, 
Germany 
Laboratory paper cloth (20,5 cm 20 cm) Kimberly- Clark Europe Limited, Kings Hill, UK 
Laser Scanning Spectral Confocal Microscope 
Leica TCS SP2 
Leica Mikrosysteme Vertrieb GmbH, Wetzlar, 
Germany 
Latex gloves Mikroflex Corporation, Vienna, Austria 
LUMITRAC 600 96-well plate Greiner Bio-One GmbH, Frickenhausen, Germany 
Microwave AFK Deutschland GmbH, Hamburg, Germany 
Multiple  
Channel pipette 50 – 200 µl 
Eppendorf AG, Hamburg, Germany 
Multitex cleaning serviettes Zellstoff-Vertriebs-GmbH & Co. KG, Troisdorf, 
Germany 
NanoDrop ND-1000 Spectrophotometer PEQLAB Biotechnologie GmbH, Erlangen, Germany 
Nikon Eclipse TS100 microscope Nikon Instruments Europe B.V, Amstelveen, 
Netherlands 
Nitrile gloves GE Healthcare Europe NV, Brussels, Belgium 
Para film American National Can, Chicago, U. S. A. 
PCR chamber G&P Kunststofftechnik, Kassel, Germany 
PCR tubes (0.2 ml) Biozym, Scientific GmbH, Oldendorf, Germany 
PCR tubes (0.2 ml) Greiner Bio-One GmbH, Frickenhausen, Germany 
Petri dishes 10 cm diameter Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips with filter (0.1 - 10 µl, 1.0 - 100 
µl, 101 - 1000 µl) 
Starlab GmbH, Ahrensberg, Germany 
Pipette tips without Filter (0.1 - 10 µl, 1.0 - 
100 µl, 101 - 1000 µl) 
Starlab GmbH, Ahrensberg, Germany 
Pipettes Hirschmann Laborgeräte GmbH & Co. KG, Eberstadt, 
Germany 
Safe Lock Tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf AG, Hamburg, Germany 
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Scale Satorius, Göttingen, Germany 
Sterile chamber Heraeus Sepatech GmbH, Osterode, Germany 
Thermo cycler Biometra GmbH, Göttingen, Germany 
Thermo mixer Eppendorf AG, Hamburg, Germany 
Vortex Bender & Hobein AG, Zürich, Switzerland 
Waste bags (300 mm x 200 mm) Lab Logistic Group GmbH, Meckenheim, Germany 
 
2.1.13 Software 
The following is a list of the software that was used with their respective acquisition 
trademark. 
Software Company 
Adobe Photoshop Adobe, San Jose, California, U. S. A. 
FLUOstar OPTIMA Version 1.32 R2 BMG LABTECH GmbH, Offenburg, Germany 
Microsoft Office 2007 Microsoft Inc., Redmond, Washington, U. S. A. 
ND-1000 V 3.3.0 one channel PEQLAB Biotechnologie GmbH, Erlangen, Germany 
NIS Elements Br Nikon, Düsseldorf, Germany 
Windows XP Microsoft Inc., Redmond, Washington, U. S. A. 
 
2.2 Methods 
2.2.1 Maintaining Cell Lines 
General methodical principles: 
To avoid overgrowth of cells and cell damage, the cells are split approximately two times in a 
week. The different cell lines are stored in T75 (75 cm²) cell culture bottles at 37 °C and in a 5 
% CO₂ atmosphere. 
Procedure: 
The 293 and Vero E6 cell lines are each cultivated in 12 ml of DMEM and the BSR-T7 cell line in 
12 ml of DMEM that contains 120 µl of G418. The splitting process is carried out as follows: 
The culture medium is removed from the culture bottles and the adherent cells are washed 
with 4 – 5 ml of PBS to get rid of residual FCS (which contains a potent inhibitor of trypsin). 1 
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ml Trypsin is added and incubated for 2 min at RT. Light hitting of the bottle on its side helps 
to detach the cells. 4 ml of the cell growth medium DMEM (ready-to-use) is added to the cell 
suspension. Approximately 0.5 ml of this suspension is refilled into the culture bottle and the 
rest discarded. The bottle is filled with 11.5 ml medium to attain its initial 12 ml (equivalent to 
a cell split ratio of 1:10). In the case of the BSR-T7 cell line, 120 µl G418 is then added. The 
cultivation bottles are then placed into the cell incubator. 
G418 is an aminoglycoside antibiotic that interferes with 80 S ribosomes, blocking protein 
synthesis. It is used for the selection of eukaryotic cells that have been stably transfected with 
neomycin resistance genes (e. g. the BSR-T7 cell line).  
 
2.2.2 Determining Cell Number 
General methodical principles: 
It is of utter importance that experiments remain comparable. To achieve this, the cells are 
counted before an experiment is carried out on them. 
Procedure: 
10 µl of the cell suspension (made up of 1 ml trypsin and 4 ml DMEM) that was collected 
during the splitting process (see 2.2.1, Maintaining Cell Lines) is pipetted into a 1.5 ml tube.  
90 µl of Trypan Blue is then added to make the cells more visible under the microscope. 10 µl 
of this new suspension is pipetted into a Neubauer cell-counting chamber. The cells in 
approximately 3 squares are counted and the average calculated. The cell number is then 
estimated using the following formula: Average x 10⁵ = Number of cells per 1 ml of cell 
suspension. 
 
2.2.3 Transformation of Plasmid-DNA 
General methodical principles: 
Plasmid-DNA being used during experiments somehow has to be multiplied. E. coli, if made 
competent, has the ability to incorporate DNA that is in its immediate environment. In nature, 
this process is aimed at, for e. g. transferring antibiotic resistance between bacteria. These 
competent E. coli replicate the plasmid-DNA that they incorporate. Each plasmid being used 
has a gene that induces resistance to the antibiotic, ampicillin. Therefore, the bacteria that 
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contain enough of this plasmid and are replicating it efficiently are resistant to ampicillin. 
Placing the bacteria now on a LB-ampicillin-agar plate selects only these resistant bacteria.  
Ready-to-use competent bacteria were used for all transformation procedures 
Procedure: 
The competent E. coli strain XL1 blue stored at -80°C is left to slowly warm up by placing the 
tube containing the cells on ice. 1 µl of plasmid-DNA is then added directly to the XL1 blue 
bacteria and shortly stirred. The bacteria are then immediately placed back on ice and left for 
30 min. Subsequently, the bacteria are streaked on a LB-ampicillin-agar plate and incubated 
over night at 37 °C.  
 
2.2.4 Plasmid-DNA Purification 
General methodical principles: 
A colony of resistant bacteria is picked from the LB-ampicillin-agar plate and is used for 
inoculation of 5 ml LB-ampicillin medium. The tube is then placed in an incubator shaker at 
150 rpm and 37 °C for 6 hours. 1 ml of this mixture is then pipetted into an Erlenmeyer flask 
containing 50 ml of the LB-ampicillin medium. The flask is then placed in the incubator shaker 
for 16 hours at 150 rpm and 37 °C.  
The plasmid-DNA now has to be extracted from the bacteria and purified of other bacterial 
components (see Plasmid-DNA Purification, 2.2.4). For this, the NucleoBond PC100 system is 
used. This system employs an alkaline/SDS lysis procedure to lyse the bacteria releasing both 
chromosomal and plasmid DNA. They are both however in a denatured form under such 
alkaline conditions. A potassium acetate buffer is then added to this denatured lysate. This 
precipitates chromosomal DNA and other cellular compounds. Plasmid-DNA, which remains in 
solution, can revert to its native super coiled structure when the solution is neutralized by the 
potassium acetate buffer. A NucleoBond column with equilibration buffer is used in the 
system to bind the plasmid-DNA to an anion-exchange resin. After repeated washing of the 
column, the bound plasmid-DNA is eluted under high-salt conditions. The eluted DNA is then 
precipitated by adding 2-Propanol. The DNA pellet is then washed twice with 70 % Ethanol to 
remove the salt used for elution. After briefly drying the DNA pellet, it is then dissolved in 
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distilled water. The amount of plasmid now just has to be determined (see 2.2.5, 
Quantification of Plasmid-DNA using NanoDrop). 
Procedure: 
The purification of plasmid-DNA is carried out according to the manual provided by the 
manufacturer (Macherey-Nagel). 
   
2.2.5 Quantification of Plasmid-DNA using UV spectrometry 
General methodical principles: 
It is necessary that the concentration of the purified plasmid-DNA be determined. The 
NanoDrop® ND-1000 Spectrophotometer is used for analyzing the DNA samples. A pulsed 
xenon flash lamp is the light source that produces ultraviolet light of 260 nm wavelength and a 
linear CCD array is used to detect the light after passing through the sample. Nitrogenous 
bases (purine and pyrimidine) in DNA absorb this ultraviolet light. Bases have their peak 
absorption at the wavelength 260 nm. The amount of light absorbed when passing through 
the sample is therefore directly proportional to the concentration of DNA in the sample. 
Procedure: 
A 1.5 µl plasmid-DNA sample is pipetted onto the end of a fiber optic cable (the receiving 
fiber). A second fiber optic cable (the source fiber) is then brought into contact with the liquid 
sample causing the liquid to bridge the gap between both fiber optic ends and the 
measurement is carried out. 
 
2.2.6 Transfection of eukaryotic cells with Plasmid-DNA 
General methodical principles: 
For introduction of plasmid-DNA into eukaryotic cells Lipofectamine 2000 (Invitrogen) is used. 
This is a formulation of cationic and neutral lipids that complexes with nucleic acids : the 
charged side of the cationic lipid interacts with the negatively charged DNA, with its  neutral 
lipid chain sticking outwards away from the DNA. The neutral lipids also in the mixture 
associate with this neutral tail of the cationic lipids, thus allowing fusion with the lipid cell 
membrane. This fusion allows the complexed plasmid-DNA, which is negatively charged, to be 
transferred over the cellular membrane and into the cell.   
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Procedure: 
The 293 cell line is chosen, because this cell line has one of the highest transfection 
efficiencies when using Lipofectamine 2000 for transfection. 24 hours before transfection, the 
cells are seeded at 1 x 10⁵ cells per well (see 2.2.2) in a 12-well plate in 1 ml DMEM (ready-to-
use). The cells are grown for 24 hours under their normal growth conditions (37°C and 5 % 
CO₂). 2 µl of the Lipofectamine Reagent is diluted in 50 µl of Opti-MEM I Medium for each 
well. The mixture is incubated at room temperature (15 – 25°C) for 5 min. During this time, the 
different corresponding are diluted in 55 µl of the Opti-MEM I medium and vortexed for a few 
seconds. Both mixtures (plasmid and the reagent) are added together and incubated for 20 
min at RT to allow formation of DNA-lipid complexes. 100 µl of this mixture is then added to 
the well containing the cells and DMEM (ready-to-use). The plate is gently rocked back and 
forth. The cells are subsequently incubated under their normal growth conditions (37°C and 5 
% CO₂) for 24 h. They are then lysed and the firefly and renilla luciferase activities are 
measured (see 2.2.10). 
Experiments concerning the transcription factors IRF-3, NF-B and AP-1: In the test series of 
reporter assays 0.25 µg of the reporter plasmids is transfected per well, unless otherwise 
stated (see Results). An equivalent amount of pUC19 (0.25 µg) is transfected into 
corresponding wells and serves as the control. 
0.5 µg of the plasmids expressing either the OROV NSs protein (pI.18-OROV-NSs-FLAG) or that 
of the RVFV (pI.18-RVFV-NSs-Z1) is transfected per well. In corresponding wells, the equivalent 
amount of the empty vector (pI.18) is transfected.  
12.5 ng of pRL-SV40 that serves as the control is transfected per well, unless otherwise stated 
(See Results). 
 
2.2.7 Generating RNA from Plasmid-DNA by in vitro Transcription 
General methodical principles: 
Here, plasmid-DNA is transcribed into RNA by in vitro transcription using the T7 RNA 
polymerase. The DNA plasmids that were transcribed here into RNA all have the T7 promoter 
(pTM1-FFLuc and pT7-riboSM2-cMpro cRL).  
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A mixture containing the T7 RNA polymerase and the four different triphosphate nucleotides 
is incubated. The polymerase binds specifically to the T7 promoter of the plasmid DNA and 
catalyzes the synthesis of complement RNA in the 5´→ 3´ direction based on the DNA 
template. This polymerase is one of very active bacteriophage polymerases that easily 
transcribes plasmid-DNA in a cell-free milieu to RNA. Unlike the eukaryotes RNA polymerase II 
that requires a number of cofactors for promoter binding, this T7 RNA polymerase is 
uncomplicated and can synthesize RNA without these additional factors. Once the RNA 
created in vitro is introduced into a cell, the cell begins its translation into protein. Therefore, 
here, the translation process of the cell is analyzed independent of the preceding 
transcription. 
Procedure: 
The in vitro transcription is carried out as follows: distilled, DNase- and RNase-free water is 
added to 2 µg of plasmid-DNA such that the total volume is 10 µl. 10 µl of 10 x transcription 
buffer, 5 µl of 1 mg/ml BSA, 5 µl of 0.1 M DTT, 5 µl RNase inhibitor, 16 µl 2.5 mM rNTP (2.5 
mM per rNTP), 47 µl distilled (DNase/RNase-free) water and 2 µl T7 RNA polymerase are all 
added. This mixture of 100 µl is incubated at 37 °C for 1.5 h. After this incubation period, 11 µl 
of 10 x DNase buffer and 1 µl of Ambions rDNase I (Ambions DNA-free™ Set) are added to 
destroy the DNA template. The mixture is incubated at 37 °C for 30 min. 10 µl of DNase 
Inactivation Reagent (Ambions DNA-free Set) is then added and the mixture is left at room 
temperature (15 – 25 °C) for 2 min and then mixed shortly. The mixture is centrifuged for 1.5 
min at 10,000 g and the supernatant transferred to a new 1.5 ml vial. 6.7 µl of 7.5 M 
Ammonium acetate is added and then 110 µl Isopropanol to precipitate the newly transcribed 
RNA. The vial is cooled for at least 15 min at -20 °C and is then centrifuged for 15 min at 
12,000 g. The supernant is discarded and the RNA pellet is washed twice with 200 µl 75 % 
ethanol each time; in between washes, the cup is centrifuged for 10 min at 10,000g. After 
drying the RNA pellet 50 µl of distilled (RNase-free) water is added to resuspend the RNA. The 
RNA is quantified using RiboGreen (see Quantification of RNA using RiboGreen, 2.2.8). The 
RNA solution is then stored at -20 °C. 
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2.2.8 Quantification of RNA using RiboGreen 
General methodical principles: 
In determining the concentration of the RNA generated from the in vitro transcription of 
Plasmid-DNA, the Quant-iT RiboGreen RNA Assay is utilized. This RiboGreen RNA 
quantification relies on a dye that exhibits a large fluorescence enhancement upon binding to 
RNA (and other nucleic acids). The fluorescence emission is in linear correlation with the 
amount of RNA. The fluorescence is measured with the FLUOstar OPTIMA reader and the 
FLUOstar OPTIMA software calculates the concentration of the sample RNA based on 
comparisons with a ribosomal RNA standard (16S and 23S rRNA from E. coli) in different 
dilutions. Falsely high concentrations due to RNA degradation are reduced by this system 
because free nucleotides are not detected. 
Procedure: 
The quantification procedure is carried out according to the manual of the manufacturer 
(Invitrogen). 
 
2.2.9 Transfecting Cells with RNA 
General methodical principles: 
In gene expression, a cellular gene (DNA) is transcribed into RNA, after post-transcriptional 
modification, this RNA as mRNA is transported out of the cell nucleus into the cytoplasm and 
ribosomes translate the ribonucleic sequence into an amino acid sequence (protein). So, 
artificially introducing (transfecting) RNA into a cell skips the transcriptional step and allows 
direct translation of the encoded protein. 
TransMessenger transfection reagent is used for combined DNA and RNA transfection. 
TransMessenger transfection reagent is based on a lipid formulation and is used with a specific 
RNA-condensing reagent (enhancer R) and an RNA-condensing buffer (buffer EC-R), all 
included in the transfection reagent set. In the first step of TransMessenger-RNA complex 
formation, the RNA is condensed by interaction with enhancer R in a defined buffer system. In 
the second step, the TransMessenger Transfection Reagent (included in set) is added to the 
condensed RNA to produce TransMessenger-RNA complexes. The TransMessenger-RNA 
complexes are then mixed with antibiotics-free medium and added directly to the cells.  
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Procedure: 
The procedure is carried out as follows: 24 hours before transfection, the cells are seeded at 1 
x 10⁵ cells per well (see Determining Cell Number, 2.2.2) of a 12-well plate in 1 ml DMEM 
containing antibiotics (PS). The cells are then incubated under their normal growth conditions 
(37 °C and 5 % CO₂). 2 µl of Enhancer R is diluted in Buffer EC-R. A total of 1 µg of RNA/DNA is 
added and mixed by vortexing for 10 s. The final volume is always adjusted to 100 µl. The 
mixture is incubated at room temperature (15 – 25 °C) for 5 min, and is then spun down for a 
few seconds to collect drops from the top of the tube. 4 µl of TransMessenger Transfection 
Reagent is added and pipetted up and down 5 times. Samples are incubated for 10 min at 
room temperature (15 – 25 °C) to allow transfection-complex formation. During this process, 
growth medium is gently aspired from the wells. The cells are washed once with 2 ml PBS. 300 
µl of DMEM without FCS and antibiotics is added to the tube containing the transfection 
complexes and mixed by pipetting up and down twice. The mixture is then immediately added 
drop-wise onto the cells and the plate is swirled gently. The cells are then incubated under 
normal growth conditions for 4 hours. Subsequently, the mixture is removed from the cells, 
followed by a washing step with 2 ml PBS and then 1 ml DMEM with FCS and antibiotics is 
added to the cells. The cells are incubated under normal growth conditions for another 24 
hours and then lysed and the protein expression was analyzed using the Dual-Luciferase 
Reporter Assay System (see Dual-Luciferase Reporter Assay 2.2.10).  
 
2.2.10 Dual-Luciferase Reporter Assay 
General methodical principles: 
This system is used to study the promoter activities using an indirect readout: light emission 
as a consequence of enzymatic activity. The “dual reporter” refers to the simultaneous 
expression of two individual enzymes in transfected cells. In this Dual-Luciferase Reporter 
Assay, the activities of the firefly (Photinus pyralis) and the renilla (Renilla reniformis) 
luciferases are sequentially measured. Firefly luciferase (a 61 kDa enzyme) and the renilla 
luciferase (a 36 kDa enzyme) do not require post-translational modification to emit 
luminescent signals. Thus, they function as genetic reporters immediately upon translation. 
The firefly luciferase cDNA is fused with different promoters and expression levels measured 
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under different conditions (see Results). The renilla luciferase gene is fused with a 
constitutively active promoter SV40 (pRL-SV40, Promega), and hence mainly served as the 
control.  This control (renilla luciferase activity) is necessary to ensure similar transfection 
efficiencies between different cell groups such that differences observed in firefly luciferase 
activity are a consequence of different promoter activities rather than a consequence of 
different transfection efficiency.  
Procedure: 
The Dual-Luciferase Reporter Assay is carried out as follows: 24 h post transfection the growth 
medium is removed from the transfected cells grown in 12 well plates. 100 µl of PBS is gently 
applied to wash the surface of the cell monolayer. The 12-well plate is then gently swirled to 
remove detached cells and residual growth medium. This PBS mixture is then completely 
removed. 100 µl of the 1 x PLB is added to each of the 12 wells and swirled to ensure complete 
coverage of the cell monolayer. The 12-well plate is intermittently rocked during a 20-minute 
incubation time at room temperature (15 – 20 °C). The wells are then scraped vigorously with 
a pipette. 20 µl of this cell lysate is transferred into a well of a Lumitrac 600 96-well plate. 100 
µl of ambient temperature LAR II is added to the lysate. The Lumitrac 600 96-well plate is then 
immediately placed in the FLUOstar OPTIMA reader and the firefly activity is measured. During 
measurement, the Renilla luciferase substrate (Stop & Glo Reagent) is prepared: for each 
assay, 2 µl of Stop & Glo Substrate is mixed with 100 µl of the Stop & Glo Buffer. 100 µl of this 
Stop & Glo Reagent is then added to each well of the 96-well plate once the firefly luciferase 
measurement is done. The renilla luciferase activity is then measured.    
 
2.2.11 Immunofluorescence 
General methodical principles: 
Immunofluorescence is the labeling of cell structures, intracellular or surface molecules using 
specific antibodies. The visualization can either be direct (i. e. the primary antibody is coupled 
to a fluorescent dye) or indirect. Indirect Immunofluorescence is used throughout this study. It 
employs two types of antibodies: the primary antibody that is targeted at the antigen of 
interest and the secondary, dye-coupled antibody that is subsequently added and recognizes 
the primary antibody. The antibodies of different species have different constant regions and 
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are therefore only recognized by specific secondary antibodies, for e. g. antibodies generated 
in a goat against a particular antigen have the goat’s constant region. The secondary antibody, 
that is dye-coupled, has to recognize the primary antibodies’ constant region. Then, using a 
microscope that emits light of a particular wavelength, the dye coupled to the secondary 
antibody is excited and emits light of a different wavelength. A photo detector or digital 
camera detects this emission. The information is then compiled in the computer as an image. 
Procedure: 
The immunofluorescence staining is carried out as follows: The cell line Vero E6 is used, 
because this cell line tightly adheres to surfaces. Glass cover slips are placed into the wells of a 
12-well plate. Vero E6 cells are seeded at 0.5 x 10⁵ cells per well of this 12-well plate (see 
2.2.2). The cells are incubated under normal growth conditions (37 °C and 5% CO₂) for 24 h. 
The cells in the wells are then transfected with 1 µg of the relevant plasmids (see 2.2.6) and 
incubated for 24 h. Fixation of the cells is carried out by transferring the cover slips to a new 
12-well plate, which already contained 1 ml of 3% Paraformaldehyde. The cells are then 
incubated for 10 min at room temperature (15 – 20 °C). The cell monolayer is subsequently 
washed 3 times with 1 ml of 1 x PBS. The cells are then permeabilized by removing the 1 x PBS, 
adding 1 ml of 0.5% Triton X-100 and incubating for 5 min/RT. The cells are then washed 3 
times with a 1 % FCS in PBS solution. The primary antibodies are prepared by diluting them in 
an appropriate ratio in 1 % FCS in PBS: the mouse antibodies H5 and H14 were used in the 
ratio of 1:100 respectively, the mouse monoclonal ANTI-FLAG M2 antibody in the ratio of 
1:200, the rabbit ANTI-FLAG polyclonal antibody in the ratio of 1:200, and the rabbit N20 
antibody was used in the ratio of 1:50. These were the ratios that were produced the clearest 
results and were always used throughout the experiments. 1 µl ToPro 3 Iodide is then added 
to this primary antibody dilution for counterstaining the cell nuclei. 
The solution in the wells is removed, and 40 µl of the primary antibody mix is then carefully 
placed onto the cover slips drop-wise and left for 1 h at RT. Then, the cell monolayer is washed 
three times with 1 % FCS in PBS. The secondary antibodies are diluted in 1 % FCS in PBS 
according to their recommended working concentration and placed onto the cover slips: the 
Cy 3-conjugated anti-mouse antibody was always used in the ratio of 1:100 and the FITC-
conjugated anti-rabbit antibody in the ratio of 1:80 for each experiment. 1 µl ToPro 3 Iodide is 
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again added to the secondary antibody dilution and the mixture is incubated with the cells for 
1 h at RT. Subsequently, they are washed three times with 1% FCS/PBS. The cover slips are 
shortly dipped into a Petri dish containing distilled water and excess water is carefully 
removed from the cover slip. A drop of mounting medium (Fluosafe, Calbiochem) is placed on 
an glass slide and the cover slip, with the cell monolayer facing down, is placed into this drop 
of mounting medium. The slides are then stored at RT until the mounting medium is solidified 
and afterwards at 4 °C and in darkness until immunofluorescence analysis.  
 
2.2.12 Minireplicon system 
Minireplicon systems are powerful tools in analyzing transcription and replication of RNA 
viruses in the absence of infectious virus. For a few of the members of the Bunyaviridae family 
minireplicon systems already exist: For RVFV (Lopez et al. 1995), Uukuniemi virus (Flick and 
Pettersson 2001), Toscana virus (Accardi et al. 2001), Akabane virus (Ogawa et al. 2007), BUNV 
(Dunn et al. 1995), and for the La Crosse virus (Blakqori et al. 2003). 
A minireplicon system consists of a functional viral polymerase and an artificial minigenome, 
which can be transcribed and replicated by the viral polymerase. The minigenome contains a 
reporter gene, e.g. the renilla luciferase gene. The reporter gene is flanked by the non-coding 
regions at the 3’ and the 5’ ends of the wild type virus’ genomic M segment. These non-coding 
regions of the virus contain the promoters that are recognized by the viral polymerase. This 
minigenome (renilla gene + viral non-coding regions) has a genomic orientation and the 
corresponding minigenome plasmid contains the T7 promoter upstream of the minigenome. 
Once transcribed in the T7 polymerase-expressing cell line BSR-T7, the RNA transcript mimics 
the viral genome with its antisense (genomic) orientation, which serves as a template for 
transcription by the viral polymerase. The viral polymerase (L-protein) as well as the viral 
nucleoprotein (N-protein) is expressed in the cell using helper plasmids. Similar to the 
minigenome plasmid, expression is T7 polymerase dependent, the cDNAs are provided in 
sense (antigenomic) orientation and are preceded by an internal ribosomal entry site (IRES). 
These features allow synthesis of the L- and N-protein in transfected BSR-T7 cells.  
The viral N protein can encapsidate the minigenome RNA transcript and the L protein 
recognizes this as its template, therefore transcribing it to mRNA. Once this mRNA has been 
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translated into the renilla protein, an increased renilla activity is observed in the Dual-
Luciferase Reporter Assay (See 2.2.10). 
Principle: 
The aim of these experiments is to find the problem that prevented the OROV minigenome 
that we tried to set up from working properly. In order to achieve this, reporter assays (see 
above) are carried out. 
Firstly, the dysfunctionality of the OROV minireplicon is shown.  
Procedure: 
The BSR-T7 cell line is chosen here, because this cell line constitutively expresses the T7 
polymerase. The plasmids that are used are all T7-promoter controlled and should therefore 
be constitutively expressed once transfected into the BSR-T7 cells. 24 hours before 
transfection, the cells are seeded at 5 x 104 cells per well (see 2.2.2) in an 18-well plate in 1 ml 
DMEM (ready-to-use) under their normal growth conditions (37°C and 5 % CO₂). A complete 
set of experiments is carried out in 6 wells. The other 12 wells permitted a lysis at different 
times. 
3 µl of the FuGENE 6 reagent is diluted in 50 µl of Opti-MEM I Medium for each well. The 
mixture is then incubated at room temperature (15 – 25°C) for 5 min. During this time, the 
plasmids (see below) are diluted in 10 µl of the Opti-MEM I medium and vortexed for a few 
seconds to collect liquid back to the bottom of the vial. Both reagent and plasmid mixture are 
added together and incubated for 15 min at RT to allow formation of DNA-lipid complexes. 
50 µl of this mixture is then added to the well containing the cells. The plate is gently rocked 
back and forth. The cells are subsequently incubated under their normal growth conditions 
(37°C and 5 % CO₂).  After the first 24 h the cells of the first six wells are lysed, then after 36 h 
and at 48 h.  The firefly and renilla luciferase activities are then measured (see 2.2.10). 
The first set of experiments is carried out as shown in the Minireplicon Table 2. Whereby the 
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 1 2 3 4 5 6 
pUC19 - 0.3 µg - 0.3 µg - 0.3 µg 
pTM-LACV-L 0.3 µg - 0.3 µg - - - 
pTM-LACV-N 0.3 µg 0.3 µg - - - - 
pTM1-orov-cSmut - - 0.3 µg 0.3 µg 0.3 µg 0.3 µg 
pTM1-orov-cL - - - - 0.3 µg - 
pT7-ribo-LACV-vMpro-vRL 0.3 µg 0.3 µg - - - - 
pT7riboSM2-orov-vMpro-vRL - - 0.3 µg 0.3 µg 0.3 µg 0.3 µg 




The amount of the plasmid is optimized to produce higher renilla activity and the following set 
of experiments is carried out as shown in the Minireplicon Table 3: 
 
 1 2 3 4 5 6 7 8 
pUC19 - 0.6 µg - 0.6 µg - 0.6 µg - 0.6 µg 
pTM-LACV-L 0.6 µg - 0.6 µg - - - - - 
pTM-LACV-N 0.6 µg 0.6 µg - - - - 0.6 µg - 
pTM1-orov-cSmut - - 0.6 µg 0.6 µg 0.6 µg 0.6 µg - - 
pTM1-orov-cL - - - - 0.6 µg - 0.6 µg 0.6 µg 
pT7-ribo-LACV-vMpro-vRL 0.6 µg 0.6 µg 0.6 µg 0.6 µg - - - - 
pT7riboSM2-orov-vMpro-vRL - - - - 0.6 µg 0.6 µg 0.6 µg 0.6 µg 





2.2.13 Statistical analysis 
Statistical analysis of reporter assay data was performed using the two-tailed Welch’s t-test 
for the determination of p values. All reporter assays (see 3.1.1) were repeated 5 times. 
Table 2. Minireplicon: The numbers 1 to 6 refer to the wells containing the BSR-T7 cells.The 
green column is the actual test while the purple column is the control. pTM1-FFLuc was added 
to all wells and served to prove successful transfection. 
Table 3. Minireplicon: The numbers 1 to 8 refer to the wells containing the BSR-T7 cells. The green column is 




3.1 Interference of OROV-NSs with IFN-  Promoter Activation 
3.1.1 Reporter Assays 
Previous experiments have shown that cells infected with the Oropouche virus are prevented 
from inducing IFN-β (Keisers); however, the mechanism of inhibition is not yet known. The 
experiments furthermore demonstrated, that transiently expressed OROV-NSs in cells is 
sufficient to mediate this effect in a virus-free system. The following reporter assays aim at 
characterizing this phenomenon in more detail: it is known that the positive regulatory 
elements of the IFN- promoter bind IRF-3, NF-B and AP-1 (Panne et al. 2007). We 
investigated whether OROV-NSs specifically interferes with the activation of one of these 
transcription factors, whereby the first experiment (see 3.1.1.1) is meant to demonstrate that 
the activation of the IFN- promoter with its three different binding sites is indeed inhibited by 
the OROV-NSs protein. The experiments thereafter then analyze the individual transcription 
factors for inhibition (see 3.1.1.2 to 3.1.1.4).  
293 and BSR-T7 cells were used here for transfections with plasmid DNA or RNA (see 2.2.6 and 
2.2.9, respectively).  
 IFN- Promoter Activation blocked by OROV-NSs 3.1.1.1
Objective: 
Does the OROV-NSs prevent IFN-β promoter activation (and as a consequence IFN-β gene 
expression)? In other words, if we transfected a plasmid containing the IFN- gene promoter 
(fused with a reporter gene) together with the OROV-NSs-expressing plasmid into the same 
cells and try to activate the promoter, would IFN- promoter inhibition be seen?  
Description: 
A constitutively active form of the transcription factor IRF-3 is expressed in the cells of the 293 
cell line by means of transfecting them with the plasmid IRF-3(5D). The constitutively active, 
spontaneously homodimerized IRF-3(5D) binds to the IFN- promoter of the likewise 
transfected reporter plasmid p125-luc, inducing the expression of the firefly luciferase (FFLuc) 
protein (see Figure 4, “Empty Vector”). IRF-3(5D) alone was used to activate the IFN-β 
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promoter in this experiment, because it is the only factor that has been shown to have the 
ability to activate the IFN-β promoter all on its own independent of the other two 
transcription factors NF-κB and AP-1 (Hiscott et al. 1999). 
Experiment: 
293 cells were transfected with the reporter plasmid p125-luc together with the control 
plasmid pRL-SV40, which expresses the renilla luciferase (RENLuc) protein (see 2.2.6.). Three 
sets of experiments were carried out and the results of all three are displayed beside each 
other on each of the charts (see Figure 4 and Figure 5): 
 
Set 1: The plasmid expressing the OROV-NSs protein (pI.18-OROV-NSs-FLAG) was transfected 
into the cells of two wells. The IRF-3(5D) plasmid was introduced into the cells of one of these 
wells. IRF-3(5D) should normally activate the expression of p125-luc-encoded firefly luciferase 
(see Figure 4, “Empty Vector”). pUC19 was transfected into the other well and served as the 
unstimulated control. 
Set 2: The plasmid pI.18-OROV-NSs-FLAG in the above set was replaced by an equivalent 
amount of the RVFV-NSs-expressing plasmid pI.18-RVFV-NSs-Z1. The other components 
remained the same. The plasmid pI.18-RVFV-NSs-Z1 was used instead of pI.18-OROV-NSs-
FLAG because it leads to the expression of the NSs protein of the Rift Valley fever virus, which 
is known to be a very efficient inhibitor of RNA polymerase II-mediated transcription. It is 
known to inhibit IFN-β transcription even in the presence of the transcription factors IRF-3, 
NF-κB and AP-1 (Billecocq et al. 2004).  
Set 3: The pI.18-OROV-NSs-FLAG in the initial experiment was replaced by an equivalent 
amount of the empty plasmid, pI.18. This served as the control.  
 
All 6 wells with cells were transfected with p125-luc 
Cells were transfected with pUC19 
(unstimulated control) 
Cells were transfected with the IRF-3(5D) 
expression plasmid (stimulation) 
OROV-NSs 
 
RVFV-NSs pI.18 (Empty 
Vector) 




Table 2: An overview of the plasmid combinations. The cells of three wells were transfected with pUC19 (unstimulated 
control) and the cells of the other three wells were transfected with the IRF-3(5D) expression plasmid (stimulation). The 
OROV-NSs-, the RVFV-NSs-expression plasmids and pI.18 (empty vector) were transfected into the cells of each of the three 
wells. This was done for the cells of the three wells co-transfected with the IRF-3(5D) expression plasmid and the cells of the 
three wells co-transfected with pUC19 (control). The blue bars represent firefly luciferase activity of the control cells, that of 





Figure 4. Firefly luciferase activity: effect of the OROV-NSs on the IRF-3-dependent luciferase expression.  
Blue: Control (pUC19) Red: Stimulated (IRF-3(5D)) 
 
Empty Vector (Control): IRF-3(5D) apparently highly and significantly (p = 0.0005) activates the 
IFN-β promoter and as a result the expression of the firefly luciferase (see “Empty Vector” in 
Figure 4). IRF-3(5D) increases reporter gene expression by factor 22. 
RVFV-NSs and OROV-NSs: The major increase by factor 22 that one sees in the control was 
prevented in the presence of both the RVFV- and OROV-NSs. There was no increment at all to 
be seen after stimulation (transfection with IRF-3(5D)). The firefly luciferase activity in the cells 
expressing RVFV-NSs and IRF-3(5D) was even lower compared to unstimulated control cells 
expressing RVFV-NSs. The luciferase activity of the cells co-transfected with the empty vector 
pI.18 and the IRF-3(5D) expression plasmid in comparison to that of the cells expressing the 
RVFV-NSs and IRF-3(5D) was strongly diminished (453 times less, p = 0.0004). This type of 
potent suppression of IFN-β promoter activation has been described for the RVFV-NSs 
(Billecocq et al. 2004). In the corresponding sample with OROV-NSs and IRF-3(5D), the firefly 
luciferase activity likewise was greatly reduced (186 times, p = 0.0004, Figure 4, “OROV-NSs”) 
when compared to the control sample (see Figure 4, “Empty Vector”). 
The basal firefly luciferase activity in the presence of either the RVFV- or OROV-NSs was also 
diminished in comparison to that of the unstimulated control (see Figure 4, “Empty Vector”). 
The firefly luciferase activity was 14 times lower (p =0.0004) in the case of cells transfected 

























IFN-β promoter-driven FFLuc expression 
Control: IFN-β-promoter-driven 
FFLuc expression (cells 
transfected with pUC19; 
unstimulated control) 
IFN-β promoter-driven FFLuc 
expression (cells transfected with 
the IRF-3(5D) expression plasmid) 
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with the RVFV-NSs expression plasmid and 8 times lower (p = 0.0006) when the OROV-NSs 
expression plasmid was transfected. 
 
 
Figure 5. Renilla luciferase activity: internal control of transfection efficiency with pRL-SV40. 
Green: Control (pUC19) Purple: Stimulated (IRF-3(5D)) 
 
Internal Control: The renilla luciferase gene expression (RENLuc) that is driven by the 
constitutively active SV40 promoter showed some interesting results. The reporter gene 
activity was inhibited by OROV-NSs (13 times lower, p = 0.001) and RVFV-NSs (105 times 
lower, p = 0.001) when compared to the unstimulated, NSs-free control (Figure 5, “Empty 
Vector”). The RVFV-NSs protein is known to potently inhibit all cellular gene expression at the 
transcriptional level and produce similar results (Billecocq et al. 2004). The decrease in renilla 
luciferase activity after transfection of the IRF-3(5D) expression plasmid in the control (Empty 
Vector) is likely due to the IRF-3(5D)-mediated activation of endogenous IFN-β gene 
expression, which can lead to inhibition of transcription and translation (Samuel 2001). 
 Transcription Factor IRF-3 3.1.1.2
Objective: 
Does the inhibitory effect of the OROV-NSs lie in inhibiting a late step of IRF-3 activation (= 
nuclear translocation, interaction with CBP/p300 or the binding to the IRF-3-binding element 









































with the IRF-3(5D) expression
plasmid)
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intracellular pathway), do we see inhibition of the IRF-3-responsive reporter gene expression 
when OROV-NSs is present? Previous experiments showed that phosphorylated (active) IRF-3 
was present in the cell after stimulation with poly(I:C) or VSV-RNA and in the presence of the 
OROV-NSs protein (Keisers). This means that the inhibitory effect of the OROV-NSs has to lie 
downstream of IRF-3 activation (= phosphorylation).  
Description: 
Just as in the above experiment, the constitutively active form of the transcription factor IRF-3 
is expressed in the cells of the 293 cell line by means of transfecting them with the plasmid 
IRF-3(5D). This constitutively active, artificially homodimerized IRF-3(5D) binds to the 
promoter of the likewise transfected reporter plasmid p55C1B-luc, inducing the expression of 
the firefly luciferase protein. The plasmid p55C1B-luc contains an artificial promoter made up 
of five binding sites for IRF-3, the same one as it is found in the original IFN- promoter 
combined with a minimal promoter. 
Experiment: 
293 cells were transfected with the reporter plasmid p55C1B-luc and with the control plasmid 
pRL-SV40 (see 2.2.6.). Three sets of experiments were carried out and all three are displayed 
beside each other on each of the charts (see Figure 6 and Figure 7): 
 
Set 1: The plasmid expressing the OROV-NSs protein (pI.18-OROV-NSs-FLAG) was transfected 
into the cells of two wells. The IRF-3(5D) plasmid was introduced into the cells of one of these 
wells and an equivalent amount of pUC19 was transfected into the cells of the other well and 
served as the unstimulated control.  
Set 2: The plasmid pI.18-OROV-NSs-FLAG in the above set was replaced by the equivalent 
amount of the RVFV-NSs-expressing plasmid pI.18-RVFV-NSs-Z1. The other components all 
remained the same. 
Set 3: The pI.18-OROV-NSs-FLAG in the initial experiment was replaced by the empty plasmid, 






All 6 wells with cells were transfected with p55C1B-luc 
Cells were transfected with pUC19 
(unstimulated control) 
Cells were transfected with the IRF-3(5D) 
expression plasmid (stimulation) 
OROV-NSs RVFV-NSs pI.18 (Empty 
Vector) 









Figure 6. Firefly luciferase activity: effect of the OROV-NSs on the IRF-3-dependent luciferase expression.  
Blue: Control (pUC19) Red: Stimulated (IRF-3(5D)) 
 
Empty Vector (Control): IRF-3(5D) highly and significantly (166 times higher luciferase activity, 
p = 3.8-10) activates the IRF-3 responsive promoter and leads to subsequent firefly luciferase 
gene expression in the absence of NSs (see “Empty Vector” in Figure 6). 
RVFV-NSs and OROV-NSs: The results here were very similar to those of the preceding 
reporter assay. The cells that expressed OROV-NSs that were not transfected with the IRF-
3(5D) expression plasmid showed a reduction in luciferase gene expression (by factor 6, p = 

































expression after transfection of
cells with pUC19 (unstimulated
control)
IRF-3-responsive-promoter-
driven FFLuc expression after
transfection of cells with the
IRF-3(5D) expression plasmid
Table 3: An overview of the plasmid combinations. The cells of three wells were transfected with pUC19 (unstimulated 
control) and the cells of the other three wells were transfected with the IRF-3(5D) expression plasmid (stimulation). The 
OROV-NSs-, the RVFV-NSs-expression plasmids and pI.18 (empty vector) were transfected into the cells of each of the three 
wells. This was done for the cells of the three wells co-transfected with the IRF-3(5D) expression plasmid and the cells of the 
three wells co-transfected with only pUC19 (control). Firefly luciferase activity of the control cells is represented by the blue 




0.001) in comparison to the OROV-NSs-free control cells (see Figure 6). Similar results were 
seen for the cells that expressed RVFV-NSs that were not transfected with IRF-3(5D) (activity 
reduction by factor 18, p = 0.0008). The difference between the cells transfected with IRF-
3(5D) and with the OROV-NSs expression plasmid and those of the control transfected with 
the IRF-3(5D) expression plasmid (without the OROV-NSs expression plasmid) is by the factor 
of 309 (p = 3.8-10), with the RVFV-NSs-expressing cells is the difference by factor 1203  
(p = 3.4-10). 
 
 
Figure 7. Renilla luciferase activity: internal control of transfection efficiency with pRL-SV40. 
Green: Control (pUC19) Purple: Stimulated (IRF-3(5D)) 
 
Internal Control: Just as it was the case in the previous reporter assay the renilla gene 
expression was reduced (14 times lower) than that of the unstimulated control (Empty Vector) 
when the NSs protein of OROV (p = 0.0008) was present. The effect was even more 
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expression after cells were
transfected with the IRF-3(5D)
expression plasmid
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 Transcription Factor NF-κB 3.1.1.3
Objective: 
Does the inhibitory effect of the OROV-NSs lie in inhibiting the activation of the transcription 
factor NF-κB? If the activation of NF-κB is artificially induced in a cell, do we see inhibition of 
the NF-κB-dependent reporter gene expression in the presence of the OROV-NSs protein? 
Description: 
16 hours after seeding 293 cells in a 12-well plate, 0.01 µg of TNF-α was used to stimulate the 
cells of some wells. Over a complex cellular cascade of reactions, the TNF-α stimulation results 
in the activation of the transcription factor NF-κB present in the cell and it also induces NF-κB 
gene expression (Nickles et al. 2012). The activated NF-κB binds to the artificial NF-κB-
responsive promoter of the reporter plasmid p55A2-luc, inducing the expression of the firefly 
luciferase protein, whose activity is measured (see 2.2.10). 
Experiment: 
293 cells were transfected with the reporter plasmids p55A2-luc and pRL-SV40 (see 2.2.6). 
Three sets of experiments were carried out and are displayed beside each other on each of the 
charts (see Figure 8 and Figure 9): 
 
Set 1: The plasmid expressing the OROV-NSs protein (pI.18-OROV-NSs-FLAG) was transfected 
into the cells of two wells. 0.01 µg of TNF-α was added to the cells of one of these samples 
and nothing was added to the other sample, thus serving as the unstimulated control.  
Set 2: The plasmid pI.18-OROV-NSs-FLAG in the above “Set 1” was replaced by the equivalent 
amount of the RVFV-NSs-expressing plasmid pI.18-RVFV-NSs-Z1. Everything else remained the 
same. 
Set 3: The pI.18-OROV-NSs-FLAG in the initial experiment “Set 1” was replaced with the empty 
vector, pI.18, which served as the control.  
 
All 6 wells with cells were transfected with p55A2-luc 
Cells were not stimulated (control) Cells were stimulated with TNF-α 
OROV-NSs RVFV-NSs pI.18 (Empty 
Vector) 
OROV-NSs RVFV-NSs pI.18 (Empty 
Vector) 
  
Table 4: An overview of the plasmid combinations. To the cells of three wells TNF-α  was not added (unstimulated) whereas 
TNF-α was added to the cells of the other three wells  (TNF-α leads to the activation of NF-κB). The OROV-NSs-, the RVFV-NSs-
expression plasmids and pI.18 (empty vector) were transfected into the cells of each of the three wells. This was carried out 
for the cells to which TNF-α was added and for the cells in the three wells to which no TNF-α was added. Firefly luciferase 




Figure 8. Firefly luciferase activity: effect of the OROV-NSs on NF-κB-dependent luciferase expression.  
Blue: Control (Nothing added) Red: TNF-α was added to these cells 
 
Empty Vector (Control): The cells that were stimulated with TNF-α showed an increase in its 
firefly luciferase activity by the factor 47 (p = 0.0005, see Figure 8, “Empty Vector”), indicating 
efficient activation of NF-κB by TNF-α.  
RVFV-NSs and OROV-NSs:  However, when this empty vector is exchanged for the expression 
plasmid expressing either the OROV- or RVFV-NSs protein, we do not see such a major, 
significant increment at all. Rather a decrease in control luciferase activity by factor 19 (see 
Figure 8, “OROV-NSs”, p = 0.0006) and factor 60 (see Figure 8, “RVFV-NSs”, two sided p = 
0.0005) was observed in comparison to the control cells transfected with the empty 
expression vector. Firefly luciferase expression of the stimulated cells expressing OROV-NSs 
and the stimulated control (Empty Vector) differs by a factor of 177 (p = 0.0005).  
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Figure 9. Renilla luciferase activity: internal control of transfection efficiency with pRL-SV40. 
Green: Control (Nothing added) Purple: TNF-α added to the cells 
 
Internal Control: Just as it was the case in the previous experiments, the renilla luciferase gene 
expression was inhibited by RVFV-NSs and OROV-NSs.  When the NSs protein of OROV was 
present, the renilla luciferase expression level was only 0.08 (p = 0.0003) relative to the level 
of the unstimulated control (Empty Vector) and 0.008 relative to the level of the control when 
the RVFV-NSs protein was present (p = 0.0002). 
 Transcription Factor AP-1 3.1.1.4
Objective: 
Does the inhibitory effect of the OROV-NSs lie in inhibiting the activation of the transcription 
factor ATF-2/cJun (AP-1)? In other words, if the activation of AP-1 is artificially induced in a cell 
(independent of its physiologic pathway) and the OROV-NSs is present, do we see inhibition of 
the AP-1-responsive reporter gene expression? 
Description: 
Here, a MEKK expression plasmid was transfected into the cells. MEKK expression is CMV-
promoter-driven and is therefore constitutively active. It produces the kinase MEKK that kicks-
starts an intracellular cascade that ends in the activation of the transcription factor AP-1 
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transfected reporter plasmid pAP1-luc, inducing the expression of the firefly luciferase 
protein, whose activity is measured (see 2.2.10).  
Experiment: 
293 cells were transfected with the reporter plasmid pAP1-luc and with the control plasmid 
pRL-SV40 (see 2.2.6). Three sets of experiments were carried out and are displayed beside 
each other on each of the charts (see Figure 10 and Figure 11): 
 
Set 1: The plasmid pI.18-OROV-NSs-FLAG was transfected into the cells of two wells. The 
MEKK-expression plasmid pFC-MEKK was transfected into the cells of one of these wells and 
an equivalent amount of pUC19 was transfected into the cells of the other well and served as 
the unstimulated control.  
Set 2: The plasmid pI.18-OROV-NSs-FLAG in the above set was replaced by the plasmid pI.18-
RVFV-NSs-Z1. Everything else remained the same. 
Set 3: The pI.18-OROV-NSs-FLAG in the initial experiment (Set 1) was replaced by the empty 
vector, pI.18, which served as the control.  
 
All 6 wells with cells  were transfected with pAP1-luc 
Cells were transfected with pUC19 
(unstimulated control) 
Cells were transfected with pFC-MEKK 
(stimulation) 
OROV-NSs RVFV-NSs pI.18 (Empty 
Vector) 





         
       
 
 
Table 5: An overview of the plasmid combinations. The cells of three wells were transfected with pUC19 (unstimulated 
control) and the cells of the other three wells were transfected with pFC-MEKK (MEKK leads to AP-1 activation). The OROV-
NSs-, the RVFV-NSs expression plasmids and pI.18 (empty vector) were transfected into the cells of each of the three wells. 
This was done for the cells of the three wells co-transfected with pFC-MEKK and the cells of the three wells co-transfected 
with pUC19 (control). The blue bars represent firefly luciferase activity of the control cells, that of the cells transfected with 




Figure 10. Firefly luciferase activity: effect of the OROV-NSs on the AP-1-dependent luciferase expression.  
Blue: Control (pUC19) Red: Cells transfected with MEKK expression plasmid (MEKK leads to AP-1 activation) 
 
Empty Vector (Control): The firefly luciferase activity increases by almost 20 times if the cells 
are co-transfected with pFC-MEKK (see Figure 10, “Empty Vector”). The activity difference is 
highly significant with a p value of 0.0008. 
RVFV-NSs and OROV-NSs: When the empty vector was replaced by an expression plasmid for 
either the OROV-NSs or the RVFV-NSs protein, we did not see this increment at all, meaning 
that although we were artificially activating AP-1 in the cell, firefly luciferase gene expression 
was inhibited. The control firefly luciferase activity of the NSs-expressing cells also dropped, 
whereby reporter gene activity in the OROV-NSs- and RVFV-NSs-expressing cells was reduced 
by factor 53 (p = 1.09 x 10⁻⁵ and 1.12 x 10⁻⁵). The cells that were transfected with both the 
OROV-NSs and MEKK expression plasmids showed a major (1395 factor) difference in reporter 
gene expression in comparison to the control cells transfected with pI.18 and the MEKK 
expression plasmid (with a p value of 0.0007). 
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Figure 11. Renilla luciferase activity: internal control of transfection efficiency with pRL-SV40. 
Green: Control (pUC19) Purple: Cells transfected with the MEKK expression plasmid (MEKK leads to AP-1 
activation) 
 
Internal Control: Just as it was the case in all of the above experiments, the renilla luciferase 
gene expression was efficiently inhibited in the presence of OROV-NSs and RVFV-NSs. It fell to 
0.05 of the reporter gene expression seen in the control cells transfected with pUC19 (see 
Figure 11) when the NSs protein of OROV was present (with p = 0.00001) and even to 0.009 of 
the control when the RVFV-NSs protein was present (with p = 0.00001). 
 Inhibitory Effects of OROV-NSs on Transcription and Translation 3.1.1.5
Cap-independent Translation: 
Objective: 
Does the inhibitory effect of the OROV-NSs protein on the reporter gene expression (IFN-β-, 
IRF-3-, NF-κB-, AP-1-responsive and SV40 promoter-driven expression) occur on the level of 
transcription or translation? 
Description: 
The level of transcription can be skipped in a cell if a reporter plasmid is in vitro transcribed 
into RNA and this RNA then transfected into a cell instead of the DNA form of the plasmid. This 
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dependent transcription. Transfection of the in vitro transcribed RNA (see 2.2.9) makes the 
expression of the luciferase gene, which is encoded on the RNA, independent of RNAP II and 
solely dependent on translational processes. Ribosomes interact with the 5’ cap end of mRNA: 
the 40S ribosomal subunit binds to this cap region and from this point onwards, RNA 
translation occurs. Alternatively, ribosomes can bind to an Internal Ribosome Entry Site (IRES), 
which are RNA regions that can directly recruit the 40S ribosomal subunit in a cap-
independent way, resulting in RNA translation (López-Lastra et al. 2005). 
The DNA plasmid pTM1-FFLuc was chosen because it contains an expression cassette 
consisting of a T7 RNA polymerase promoter followed by an IRES and the FFLuc cDNA. It was 
transcribed in vitro to RNA and transfected into BSR-T7 cells. Standard guanosin was used for 
the in vitro transcription, i. e. the transcripts are not capped at the 5’ end.  
Experiment: 
0.5 µg of this pTM1-FFLuc RNA was transfected into the BSR-T7 cells of each of four wells. Into 
the cells of each of these wells, an increasing amount of the OROV-NSs expression plasmid 
was transfected, starting by transfecting no OROV expression plasmid into the cells of the first 
well (control), followed by 100 ng, 250 ng, and ending with 500 ng of plasmid. To make sure 
that the total amount of nucleic acid always remained constant between these four wells, the 
RVFV Clone 13 NSs expression plasmid was transfected to compensate for the missing nucleic 
acid when the amount of transfected OROV-NSs expression plasmid was varied. In the end,  
1 µg of nucleic acid was always transfected. The RVFV Clone 13 NSs expression plasmid (see 
2.1.8) expresses the mutated RVFV Clone 13 NSs, which has no inhibitory function on RNA 
polymerase II-mediated expression (Vialat et al. 2000).  
All cells were co-transfected with the control plasmid pRL-SV40 DNA. The experiments were 




Figure 12. Firefly luciferase activity: increasing amounts of the OROV-NSs expression plasmid was co-
transfected together with a constant amount of the luciferase expressing RNA, which was transcribed in vitro 
using pTM1-FFLuc as template. X-axis = respective OROV-NSs expression plasmid amounts transfected into the 
cells. 
 
The firefly luciferase activity dropped by only 30 % (compared to its control activity) when 100 
ng of the OROV-NSs expression plasmid was transfected (p = 0.001, see Figure 12). In contrast, 
the renilla luciferase activity (p = 0.0004, see Figure 13) dropped 24 times when 100 ng of the 
OROV-NSs expression plasmid was co-transfected in comparison to its control activity in the 
absence of OROV-NSs. When 500 ng of the OROV-NSs expression plasmid was transfected into 
the cells the firefly luciferase activity was only 2.3 times lower (p = 0.0006) compared to the 
control without OROV-NSs (see Figure 12, “500 ng” versus “0 ng”) whereas its renilla luciferase 
counterpart was 46 times lower (p = 0.0004). Although the 2.3 factor drop in firefly luciferase 
activity is significant, it was far from the 46-fold reduction seen in the RNA-polymerase II-
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Figure 13. Renilla luciferase activity: with increasing amounts of the transfected OROV-NSs expression plasmid, 
the renilla luciferase gene expression (pRL-SV40) is increasingly inhibited. X-axis = respective OROV-NSs 




Could it be that the OROV-NSs does indeed inhibit translation by specifically interfering with 
the cellular cap-dependent method of translation? 
Description: 
Eukaryotic cells cap their RNA in the cell nucleus before extranuclear transportation and the 
translation machinery recognizes this cap and begins protein synthesis. It could be that the 
OROV-NSs protein does indeed inhibit translation, in contrast to the findings of the previous 
experiment (see 3.1.1.5., “Cap-independent Translation”), and not transcription, by inhibiting 
specifically the translation of capped RNA (and not IRES-dependent translation). It was 
therefore necessary to test if the expression of an artificially generated capped reporter RNA 
was inhibited in the presence of the OROV-NSs. 
Experiment: 
The DNA plasmid pT7-riboSM2-cMpro cRL served as the template for in vitro transcription. 
This plasmid that lacks an IRES was transcribed in vitro to RNA (see 2.2.6), this time however, a 
part of the ribonucleotide GTP was replaced with its capped form (7mG(5’)ppp(5’)G): instead 
499731 
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of the 2.5 mM GTP normally added, a mixture of 2 mM of its cap analogue and 0.5 mM of 
standard GTP was added. The cap analogue to normal GTP ratio was 4:1.  
The in vitro transcribed cMpro cRL RNA was transfected into BSR-T7 cells. An increasing 
amount of the OROV-NSs expression plasmid was transfected into the cells of the respective 
wells, starting from transfecting none (control), to 100 ng, 200 ng, and 400 ng in the last well. 
The total amount of nucleic acid remained constant between the cells of the different samples 
by transfecting the RVFV-NSs Clone 13 expression plasmid, such that at the end 1 µg of nucleic 
acid (0.5 µg DNA + 0.5 µg RNA) was always transfected. The cells were always co-transfected 
with 100 ng of the constitutively active pGL3-FFLuc DNA control plasmid. 
 
Figure 14. Renilla luciferase activity: increasing amounts of the OROV-NSs expression plasmid were co-
transfected with a constant amount of the renilla luciferase expressing RNA. X-axis = respective OROV-NSs 
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Figure 15. Firefly luciferase activity: with increasing amounts of the transfected OROV-NSs expression plasmid, 
the firefly luciferase gene expression is increasingly inhibited. X-axis = OROV-NSs expression plasmid amount 
transfected. 
 
The cells that were transfected with 100 ng of the OROV-NSs expression plasmid showed a 
significant reduction (factor 13, p = 0.02) in the firefly luciferase activity when compared to the 
cells into which no OROV-NSs expression plasmid was transfected (see Figure 15). There was 
no inhibition at all observed for the translation of capped RNA in the cells expressing OROV-
NSs (see Figure 14). There was even a slight, but significant increase in the renilla luciferase 
expression to be seen when the cells were transfected with 400 ng of the OROV-NSs 
expression plasmid and the renilla luciferase expression was compared to that of the cells not 
expressing the OROV-NSs (factor 1.3, p = 0.05). 
 Effects of the OROV-NSs on the T7 DNA dependent RNA-polymerase  3.1.1.6
Objective: 
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BSR-T7 cells constitutively express the T7 polymerase and this polymerase transcribes 
expression cassettes that have the T7 promoter. The expression cassette of the plasmid pTM1-
FFLuc has such a promoter.  
Experiment: 
0.5 µg of the pTM1-FFLuc DNA plasmid was transfected into the BSR-T7 cells. Into each of the 
wells containing these cells, an increasing amount of the OROV-NSs expression plasmid was 
transfected, starting from transfecting none (control), to 100 ng, 250 ng, and ending by 
transfecting 500 ng in the cells of the last well. The total amount of transfected nucleic acid 
remained constant between the cells in the different wells by transfecting the RVFV-NSs Clone 
13 expression plasmid, such that at the end, 500 ng of nucleic acid was always transfected. 
 
Figure 16. Firefly luciferase activity: increasing amounts of the OROV-NSs expression plasmid were co-
transfected together with a constant amount of the luciferase expression DNA plasmid pTM1-FFLuc. X-axis = 
OROV-NSs expression plasmid amounts transfected. 
 
There is no significant inhibition of the expression of the pTM1-FFLuc DNA reporter plasmid to 
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the cells (see Figure 16). This is in contrast to the effects the OROV-NSs has on the SV40 
promoter-driven reporter gene expression (plasmid pRL-SV40) in the preceding experiments 
which is dependent on the eukaryotic RNA-polymerase II. 
 
3.1.2 Effects of OROV-NSs on Phosphorylation State of RNAP II 
Objective: 
Does the OROV-NSs protein reduce transcription activity by preventing the phosphorylation of 
the cellular RNA polymerase II? Alternatively, could it be that the NSs induces degradation of 
the polymerase? 
Description: 
The cellular DNA-dependent RNA polymerase II (RNAP II) is the synthesizer of mRNA. The C-
terminal domain (CTD) of the polymerase consists of 52 repeats of the sequence YSPTSPS. For 
the initiation of transcription of a gene, the RNAP II has to be phosphorylated at serine 5 of 
these repeats. Once the TFIIH kinase has catalyzed multiple of the serine 5 phosphorylations 
of the many repeats, the polymerase initiates transcription.  
The serine at position 2 of these repeats additionally has to be phosphorylated after initiation 
for the polymerase to carry out the elongation and the 3’-end processing of the transcript 
(Thomas et al. 2004). 
Antibodies are used in the following immunofluorescence experiments that bind specifically to 
either phospho-serine 5 (initiation) or to phospho-serine 2 (elongation/3’-end processing). The 
antibody against phospho-serine 5 is called H14 and that against phospho-serine 2, H5. 
Secondary antibodies that are coupled to fluorescent dyes bind to the first antibodies. The 
coupled fluorophore emits fluorescent signals of a particular wavelength after light 
stimulation (see 2.2.11). 
A third primary antibody was used: the N20 antibody is an antibody that recognizes the N 
terminus of the large subunit of the RNAP II irrespective of the CTD phosphorylation state. It 
targets the active and inactive polymerase alike. 
If for example, the serine at position 5 of the repeats is not phosphorylated, the H14 antibody 
has nothing to bind to and is washed away, leaving a dark cell nucleus when the cells are 
stimulated with light under the confocal microscope. 
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The following experiments involved transfecting Vero E6 cells with the NSs expression 
plasmids of either the OROV, the RVFV or with a control plasmid that is used for the 
expression of a protein that has no influence on CTD phosphorylation (FLAG-ΔMx). Each of 
these proteins carries a FLAG tag, against which antibodies have been generated. This so-
called anti-FLAG antibody was the fourth primary antibody used.  
Experiment: 
(See 2.2.11) The secondary bodies used in all of the following experiments were the CY3-
conjugated anti-mouse antibody and the FITC-conjugated anti-rabbit antibody. The DNA dye 
To Pro 3 Iodide was always added to the primary and secondary antibody dilutions. To Pro 3 
stains DNA in the cell nucleus. The group of cells transfected with the RVFV-NSs expression 
plasmid served as the reference, since a lot is known about the RVFV-NSs inhibition 
mechanism.  
 
Effects of NSs on transcription initiation (Figure 17):  
Vero E6 cells were transfected with the OROV-NSs, the RVFV-NSs expression plasmid or the 
FLAG-ΔMx plasmid. 24 h later, both of the following primary antibodies were added: the 
mouse antibody H14 (that binds to phospho-serine 5) together with the rabbit anti-FLAG 
polyclonal antibody (that binds to the NSs-FLAG). After a 1 h incubation period, the cells were 
washed and subsequently incubated with the secondary antibodies for another hour. 
 
Effects of NSs on transcript elongation (Figure 18): 
Vero E6 cells were transfected with the OROV-NSs, the RVFV-NSs expression plasmid or with 
the FLAG-ΔMx plasmid. 24 h later, both of the following primary antibodies were added: this 
time, the mouse antibody H5 (that binds to phospho-serine 2) was used instead of the H14 
antibody, together with the rabbit anti-FLAG polyclonal antibody that binds to NSs (FLAG 
region). After a 1 h incubation period, the cells were washed and subsequently incubated with 





Effects of NSs on the total RNAP II amount (Figure 19):  
24 h after transfection with the OROV-NSs, the RVFV-NSs expression plasmid or the FLAG-ΔMx 
plasmid, the following primary antibodies were added: the rabbit N20 antibody that binds to 
active or inactive RNAP II alike and the mouse monoclonal anti-FLAG M2 antibody that binds 
to NSs (FLAG region). After a 1 h incubation period, the cells were washed and subsequently 







Figure 17. Green represents the NSs protein of OROV, RVFV or the protein FLAG-ΔMx. Red represents the 








Figure 18. Green represents the NSs protein of OROV, RVFV or the protein FLAG-ΔMx. Red represents 







In all images, green represents a protein that has a FLAG region, so the NSs proteins (either 
that of the OROV or RVFV) or the control (FLAG-containing non-functional protein). Red is 
either the phosphorylated (H5 and H14 antibodies) or the inactive/active RNAP II (N20 
antibody). The “Merge” images are the fusion of both images to show co-localization. Yellow 
color on these merged images therefore represents an overlay of the green NSs (FLAG) with 
the red RNAP II, which means both cellular bodies to which the antibodies have bound, are in 
the same place.  
Merge RNA Pol II 
Figure 19. Green represents the NSs protein of either OROV, RVFV or the protein, FLAG-ΔMx. Red 
represents the RNAP II.  
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When closely examined, the OROV-NSs proteins seem to create structures circular in shape in 
the cell nucleus (see Figures 18, 19). 
No reduction in the phosphorylation state of serine 2 or serine 5 in the RNAP II is visible in the 
cells expressing the OROV-NSs protein (see Figures 17 and 18). There is also no weakening of 
the N20 signal in these cells. This means there is neither inactivation nor apparent degradation 
of the RNAP II in OROV-NSs-containing cells (see Figure 19). 
The images seem to show a geometrical association between the OROV-NSs and the active 
RNAP II. High signal intensity OROV-NSs nuclear regions on Figure 17 and 18 (upper panel of 
pictures, respectively) are overlaid by high intensity signals of active (= phosphorylated) RNAP 
II. In Figure 19, no obvious association is seen between the total RNAP II (both active and 
inactive) and the OROV-NSs.  
Figures 17 to 19 also show the typical filamentous structure of intranuclear RVFV-NSs, which 
has previously been described (Billecocq et al. 2004). 
In the cells expressing the RVFV-NSs protein there was apparently no inhibition of 
transcription initiation by the RNAP II (phospho-serine 5). The primary antibodies against 
phospho-serine 5 always found their target in the presence of RVFV-NSs (see Figure 17). 
Rather, elongation and/or 3’-end processing of the transcript is prevented by the RVFV-NSs: 
the H5 antibodies against phospho-serine 2 in Figure 18 were unable to bind to their targets in 
the cells transfected with the RVFV-NSs expression plasmid. The cells on the same image 
without the filamentous RVFV-NSs had enough phospho-serine 2 for high intensity signals. 
The control images (see Figure 19) all show an even distribution of pI.18-FLAG-ΔMx in the cell 
nuclei irrespective of what primary antibody was used. This distribution of protein across the 
cell is what is normally expected. No ring-like (OROV-NSs) or filamentous (RVFV-NSs) 
structures were seen in any of the control cells. 
 
3.2 The OROV Minireplicon System 
Objective: 
Previously, the Virology Institute of the Georg-August University in Göttingen set up a 
minireplicon system for the OROV. This has never been done before for the OROV. This system 
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was however inactive. Aim of the following experiments was to find the problem that 
prevented the OROV minireplicon system from working (see 2.2.12). 
Experiment: 
Reporter assays were carried out as described (see 2.2.12), whereby two sets of experiments 
were set up. The OROV minireplicon system was set up in both sets of experiments parallel to 
that of the La Crosse virus (LACV). The LACV minireplicon system is properly established; it is 
known to work and served as the control (Blakqori et al. 2003).  
OROV minireplicon (Figure 20/C and 22/C): BSR-T7 cells were transfected with pTM1-orov-
cSmut that is used for the expression of the nucleoprotein of the OROV (= OROV-N) and 
pTM1-orov-cL that is used for the expression the L protein (RNA polymerase; OROV-L) of the 
OROV.  Both of these genes are T7 promoter-driven and are therefore constitutively expressed 
in T7 polymerase-expressing BSR-T7 cells. The plasmid pT7-riboSM2-orov-vMpro-vRL, which is 
used for the expression of the OROV minigenome, was co-transfected into the same cells. 
Recognition of the minigenome by the OROV-L and –N proteins lead to the expression of the 
renilla luciferase protein, whose gene is encoded on the minigenome. 
The renilla luciferase activity of the OROV minireplicon was measured and compared to that of 
the LACV.  
LACV minireplicon (Figure 20/A and 22/A): The LACV minireplicon involved transfecting BSR-
T7 cells with pTM-LACV-L (used for the expression of the RNA polymerase of the LACV), pTM-
LACV-N (used for the expression of the LACV nucleoprotein) and the plasmid pT7-ribo-LACV-
vMpro-vRL, which is used for the expression of the LACV minigenome. The activity of the LACV 
minireplicon correlates with the expression of the renilla luciferase protein, whose activity is 
measured (see 2.2.10).  
The controls for both minireplicon systems were carried out by replacing the transfected 
plasmids with an equivalent amount of pUC19 DNA (see Figure 20/22 for replaced plasmid). 
Furthermore, to show proper handling and efficient transfection, all cells were always co-
transfected with the control plasmid pTM1-FFLuc (= used for the expression of the firefly 
luciferase). The firefly luciferase gene is also T7 promoter-controlled and is therefore 
constitutively expressed in BSR-T7 cells. 
Results 62 
In the first set of experiments (Figure 20 and 21; see also 2.2.12 and Table 2) 0.3 µg of each 
plasmid was transfected per well. The renilla luciferase activity of the LACV minireplicon in 
comparison to the control was very high showing an active system. The OROV minireplicon on 
the other hand could not show significantly higher renilla luciferase activity in comparison to 
its control (see Figure 20/C) showing an inactive system. Its activity was far from that of the 
LACV minireplicon. 
The LACV-L and –N expression plasmids were co-transfected together with the OROV 
minigenome expression plasmid (see 20/B1). This co-transfection revealed some interesting 
results (see Figure 20/B). Apparently, the RNA polymerase and nucleoprotein of the LACV, to 
some extent, recognized the OROV minigenome and this system lead to a greater expression 
of the renilla luciferase protein in comparison to the OROV system with only OROV 



































Testing the OROV and LACV Minireplicon 
Renilla luciferase expressing system
Control
A1: LACV-L + LACV-N + LACV-minigenome 
A2: pUC19 + LACV-N + LACV-minigenome 
 
B1: LACV-L + LACV-N + OROV-minigenome 
B2: pUC19 + LACV-N + OROV-minigenome 
 
C1: OROV-L + OROV-Smut + OROV-minigenome 




Figure 21. Firefly luciferase activity: internal control of transfection efficiency with pTM1-FFluc. A, B, and C 
correspond to A, B, and C in Figure 20, respectively.  
 
A second set of experiments (Figure 22 and 23; see also 2.2.12 and Table 3) was carried out 
with further variation of the components and an increase in the amounts of transfected 
plasmid from 0.3 µg to 0.6 µg per well.  The LACV-N expression plasmid in the LACV 
minireplicon was replaced by the OROV-N expression plasmid. This resulted in a major drop in 
minireplicon activity (see Figure 22/B) indicating that the nucleoprotein of the OROV was 
unable to recognize the LACV components. Like in the above set of experiments, the OROV 
minireplicon was barely active (see Figure 22/C).  
The LACV nucleoprotein and the OROV RNA polymerase expression plasmids, and the OROV 
minigenome were then co-transfected together. Here too, the minireplicon was inactive (see 
Figure 22/D). 
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Figure 22. Renilla luciferase activity. A to D show the different systems set up. 
 
 
Figure 23. Firefly luciferase activity: internal control of transfection efficiency with pTM1-FFLuc. A, B, C and D 
correspond to A, B, C and D in Figure 22, respectively.  
 
The control transfection with pTM1-FFLuc showed efficient transfection (see Figures 21 and 
23) in all sets of experiments. Notable, is the increase in firefly luciferase expression in the 



























































Control of Transfection Efficiency 
Minireplicon
Control (pUC19)
A1: LACV-L + LACV-N + LACV-minigenome 
A2: pUC19 + LACV-N + LACV-minigenome 
 
B1: LACV-L + OROV-Smut + LACV-minigenome 
B2: pUC19 + OROV-Smut + LACV-minigenome 
 
C1: OROV-L + OROV-Smut + OROV-minigenome 
C2: pUC19 + OROV-Smut + OROV-minigenome 
 
D1: LACV-N + OROV-L + OROV-minigenome 
D2: pUC19 + OROV-L + OROV-minigenome 
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Sequencing the OROV Minireplicon Components 
In further efforts to identify the problem, pTM1-orov-cL was sequenced (Seqlab Göttingen 
GmbH). The sequence was compared to that of the OROV (the Trinidad strain) that is in the 
international gene bank. It turned out that in the OROV-L gene, there were indeed six 
nucleotide insertions in comparison to the OROV sequence in the gene bank. The first five 
inserted nucleotides were adenosines and in approximately the same region of the L segment 
at positions 2936, 2945, 2949, 2968 and 2974. A very close-by thymine was also inserted at 
position 2980. These changes mean the addition of two amino acids in the protein sequence. 
Furthermore, the ORF of the OROV minigenome (i. e. the RENLuc cDNA) was sequenced and 
found to be correct. The 3`and 5`NTRs of the minigenome were initially not sequenced 
because they require special procedures due to the complement bonds they build that gives 
the minigenome its pan-like structure. After the conclusion of experiments for this thesis, it 
was found that both NTR sequences were correct in comparison to the international gene 
bank. There was however one additional nucleotide when the sequence was compared to 
those of the other Orthobunyaviruses. This was very unusual because this is a highly 





4.1 Interference of OROV-NSs with IFN- Promoter Activation 
4.1.1 Effects of OROV-NSs on IFN-β Promoter Activation 
The activation of the IFN-β promoter and subsequent IFN-β gene expression is a critical 
reaction of cells in response to viral invasion. 
Previous experiments have shown that OROV, similar to other Orthobunyaviruses, inhibits the 
expression of IFN-β in infected cells and that the viral NSs protein is responsible for this 
inhibition (Keisers). Overexpression of IRF-3(5D) in a cell can activate the IFN-β promoter 
(Hiscott et al. 1999). IRF-3(5D) mimics the hyperphosphorylated and therefore activated IRF-3. 
The phosphorylated serine residues in activated IRF-3 are replaced by phosphomimetic 
aspartic acid. Transfecting cells with the IRF-3(5D) expression plasmid and the IFN- promoter-
driven reporter gene plasmid, p125-luc, should therefore lead to a strong activation of the 
IFN- promoter. This was indeed observed in the experiments described in section 3.1.1.1. 
Here, IRF-3(5D) expression led to a 22-fold increase in IFN-β promoter activity (p = 0.0005). 
However, when either the OROV-NSs or the RVFV-NSs expression plasmid was additionally co-
transfected respectively, this increase was prevented. This supports the conclusion that the 
OROV-NSs, similar to the RVFV-NSs (Billecocq et al. 2004), inhibits the activation of the IFN- 
promoter. This result suggests that the inhibition of IFN- promoter activation by the OROV-
NSs is downstream of IRF-3 hyperphosphorylation. 
The corresponding control renilla luciferase activity was however also diminished when either 
the OROV- or RVFV-NSs expression plasmids were respectively co-transfected (see Figure 5). It 
is therefore theoretically possible that the NSs proteins are cell toxic and the observed 
prevention of IFN- promoter activation is indeed a pseudo one. Under the light microscope, 
the cells were inspected and their population had notably increased over the 24 h incubation 
period (between transfection and lysis). A cell toxic effect has not been described for the NSs 
proteins of the other Bunyaviruses. It is therefore unlikely that cell toxicity played a major role 
in the observed results. However, it cannot be excluded with complete certainty that 
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transfected cells primarily died and were replaced by non-transfected, growing cells. Further 
experiments should be performed to formally rule out toxicity of OROV-NSs.  
 
The first step in trying to identify where the OROV-NSs protein prevents IFN-β promoter 
activation lay in determining if it inhibits the activation/expression of any of the three 
transcription factors (TF) that lead to IFN-β gene expression during viral infection: IRF-3, NF-κB 
and/or AP-1 (Hornung et al. 2006, Kato et al. 2011).  
Quite a number of viruses have evolved to inhibit the IFN system by targeting a step in the 
activation of the TFs that bind specifically to the IFN- promoter. For e. g. the Influenza A virus 
expresses the NS1 protein once inside a cell. NS1 efficiently prevents the activation of all of 
the three factors, IRF-3, NF-κB and AP-1 (Talon et al. 2000, Wang et al. 2000, Ludwig et al. 
2002). The VP35 protein of the extremely deadly Ebola virus inhibits the activation of IRF-3 
(Basler et al. 2003). 
Experiments were carried out to uncover a potential inhibition: each of the TFs were 
respectively activated (NF-κB, AP-1) or a constitutively active mutant form (IRF-3) 
overexpressed in 293 cells and their TF-specific reporter gene expression plasmids were 
transfected into these cells together with the OROV-NSs expression plasmid. This meant that 
we by-pass the individual activation pathway of each of the TFs by artificially having them 
activated or by having a mutant constitutively active form overexpressed in the cells. The NSs 
should therefore lose its inhibitory effect on reporter gene expression if its mechanism of 
inhibition was indeed preventing the IFN-β pathway-specific activation of one of the three TFs 
necessary (see 3.1.1.2 to 3.1.1.4). 
Co-transfection with the IRF-3(5D) expression plasmid and the IRF-3-responsive reporter gene 
plasmid (p55C1B-luc) showed in the absence of OROV-NSs a 166-fold increase in the firefly 
luciferase reporter activity which was highly significant (p = 3.8-10). Additional transfection of 
the OROV-NSs expression plasmid strongly inhibited (p = 3.8-10) this activation (see Figure 6, 
3.1.1.2). That means that the OROV-NSs protein acts inhibitory even in the presence of the 
activated TF, IRF-3. Similar to the results described above (see 3.1.1.1), it apparently inhibits 
IFN expression somewhere downstream of the early steps of IRF-3 activation 
(phosphorylation, homodimerization). The early steps of the IRF-3 activation pathway are 
Discussion 68 
therefore not significant for the inhibitory effect of NSs. Transfection with the RVFV-NSs 
expression plasmid served as the control since it is known that the RVFV-NSs does not inhibit 
IRF-3 activation, but rather works downstream of its activation (Le May et al. 2004). The 
results for the RVFV- and OROV-NSs proteins are similar.  
The same procedure was carried out, this time artificially inducing the activation of NF-κB by 
adding TNF- to the cells. Similar results were seen as with the IRF-3(5D), also indicating that 
the OROV-NSs protein can inhibit NF-κB-mediated promoter activation even in the presence of 
activated NF-κB (see 3.1.1.3). Similar results were observed, when AP-1 was artificially 
activated (via the MEKK pathway) in cells co-transfected with the AP-1-responsive reporter 
plasmid together with the OROV- and RVFV-NSs expression plasmids, respectively. The 
reporter gene expression was always inhibited (see 3.1.1.4). All results correlate with those of 
the RVFV-NSs, indicating that the OROV-NSs works in a similar way: inhibition of IFN- 
promoter activation by OROV-NSs cannot be attributed to the inhibition of a specific TF.   
The consistent inhibition (diminished renilla luciferase activity) of the constitutively active 
SV40 promoter-mediated Renilla luciferase reporter gene expression when either the OROV- 
and RVFV-NSs was present (see Figures 5, 7, 9, 11, 13), suggests that it is not an inhibitory 
process specific to the IFN-β promoter, but rather also to other promoters (even the 
constitutively active ones).  The inhibitory effect mediated by OROV-NSs is apparently not 
promoter specific. This suggests that either the general gene transcription machinery of the 
cell could be the target of the NSs or inhibition lies at the later step of mRNA translation, or 
maybe a combination of both.  
Both BUNV-NSs and RVFV-NSs have been shown to be inhibitors of RNAP II albeit by usage of 
different mechanisms (Thomas et al. 2004, Kalveram et al. 2012, Ikegami et al. 2009, Billecocq 
et al. 2004). It is therefore likely that OROV-NSs is also a general inhibitor of RNAP II-mediated 
transcription which would explain the reduction of hCMV promoter-driven Renilla luciferase 
reporter gene expression. 
It is worth noting the potency of these NSs proteins to inhibit promoter activity: transfection 
with 500 ng of OROV-NSs expression plasmid resulted in the prevention of the reporter gene 
expression increment of factor 166 when IRF-3(5D) was present (see Figure 6). Its intense 
potency is also shown by the fact that only 100 ng of the transfected OROV-NSs expression 
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plasmid resulted in a decrement of expression of the constitutively active SV40 promoter-
driven reporter gene (pRL-SV40) by factor 33 (see Figure 13). The control transfections with 
the RVFV-NSs expression plasmid showed even a greater potency.  
 
4.1.2 Effects of OROV-NSs on General Gene Transcription and on Translation 
The above experiments show strong inhibition of reporter gene expression by the NSs protein 
independent of the promoter used. This leads to the question: does the NSs inhibit cellular 
transcription or translation? 
Experiments were carried out that skipped the cellular transcriptional process and tested the 
translation directly: an in vitro transcribed reporter RNA that expresses the firefly luciferase 
protein was co-transfected together with the OROV-NSs expression plasmid. The reduction of 
firefly luciferase protein expression would point towards a translation inhibition (since 
translation of RNA to protein is obviously independent of the transcription machinery). 
The inhibition of gene expression of pRL-SV40 DNA (Figure 13, control) and pGL3 DNA (Figure 
15, control) was compared to the inhibition of the firefly luciferase protein translation from in 
vitro transcribed RNA in the presence of the OROV-NSs (see Figures 12 and 14).  When 100 ng 
of the OROV-NSs expression plasmid was co-transfected into cells that contained both the 
firefly luciferase reporter RNA and either of the DNA controls, pRL-SV40 and pGL-FFLuc, cap-
independent translation of reporter RNA was not inhibited by OROV-NSs since firefly 
luciferase activity was reduced by only 2.3 times. However, a major inhibition of DNA-encoded 
luciferase activity was seen. The control renilla activity was reduced by 24 times (p = 0.0004) 
and 13 times (p = 0.02) for the control firefly luciferase activity. These findings point towards 
the inhibitory function of OROV-NSs on the transcriptional level.  
Figure 12 shows that the cap-independent translation was not inhibited by OROV-NSs. 
However, mRNA transcribed in the cell nucleus is capped and translocated to the cytoplasm. 
This capped form is recognized and translated by the cellular ribosomes. It has to be 
considered that it is possible that the OROV-NSs inhibits only the 5’ cap-dependent translation 
of cellular mRNA. The in vitro generated RNA in the experiments described under 3.1.1.4 was 
uncapped, because it contained an IRES as an alternative site for translation initiation (López-
Lastra et al. 2005). Therefore, the effect of OROV-NSs on cap-dependent translation was 
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additionally tested by usage of an in vitro transcribed RNA which did not contain an IRES but 
rather carried a cap-analog at the 5’ end. Figure 14 shows the effects the OROV-NSs has on 
capped RNA translation (see 3.1.1.5). Similar to cap-independent translation OROV-NSs had no 
inhibitory effect on cap-dependent translation. It is therefore acceptable to assume that 
translation inhibition does not play a significant role in the pathogenicity of the OROV-NSs 
protein. 
 
4.1.3 Effects of OROV-NSs on the cellular DNA-dependent RNAP II 
All of these results combined suggest that it is indeed the cellular transcription that is inhibited 
by OROV-NSs. This assumption is supported by the observation (see Figure 16) that OROV-NSs 
had absolutely no inhibitory effect on the T7 promoter-driven reporter gene expression. In 
other words, neither the T7 RNA polymerase-mediated transcription (foreign T7 polymerase) 
nor translation (cellular machinery) is inhibited. The T7 system apparently has the ability to 
bypass the NSs inhibitory effect.  
The OROV-NSs apparently has an inhibitory effect on RNAP II-dependent promoters, 
supporting the fact that it is the RNAP II being inhibited (maybe RNAP I and RNAP III too). The 
BUNV, which is of the same genus as the OROV (Orthobunyavirus), and the Phlebovirus RVFV 
are known to both inhibit the cellular RNAP II. However, both use different strategies (see 
below).  
Normally, the RNAP II binds to the IFN-β gene promoter (as it does to other promoters) in the 
presence of basic and specific TFs. After binding of RNAP II to the promoter, the serine 
residues at position 5 of the 52 hepta repeats (repeat amino acid sequence: YSPTSPS) in the 
RNAP II C-terminal domain (CTD) are then reversibly phosphorylated. Transcription is 
subsequently initiated but then pauses without further modification. Elongation and the 3’-
end processing of the nascent transcript requires additional phosphorylation of the serine 2 
residues of the CTD-repeats and restarts the RNAP II (Kim et al. 1994, Thomas et al. 2004). 
The BUNV-NSs protein prevents this elongation and/or 3’-end processing of the IFN-β mRNA 
by inhibiting serine 2 phosphorylation of the RNAP II CTD (Thomas et al. 2004). This reduces 
overall gene transcription. The BUNV-NSs inhibits the cells RNAP II transcriptional activity by 
interacting with the protein MED8 (Léonard et al. 2006), which is a subunit of the mediator 
Discussion 71 
complex that interacts with the CTD of RNAP II in its hypophosphorylated form. The complex 
activates CTD phosphorylation using the TFIIH kinase (Kim et al. 1994, Kobor and Greenblatt 
2002). With such a close relative of the OROV using this strategy, it was of course critical to 
determine if the OROV-NSs exhibits the same mechanism of transcription inhibition. The RNAP 
II phosphorylation state at the serine 2 sites of the repeats would have to be looked at, when 
OROV-NSs was present. Notably, the domain of the BUNV-NSs protein that interacts with the 
MED8 complex contains an amino acid motif that is highly conserved amongst the NSs 
proteins of viruses of the Bunyamwera and California serogroups (Léonard et al. 2006). There 
is currently no data comparing these domains with that of the Simbu serogroup. 
Even though the NSs protein of the Phlebovirus RVFV has hardly any sequence similarity to 
that of the BUNV-NSs (Billecocq et al. 2004), it has been shown to also prevent the 
phosphorylation of serine 2 on the repeats (unpublished data by Dr. rer. nat. Martin Spiegel, 
Virology Institute, Göttingen). This prevents elongation and/or 3’-end processing of the IFN-β 
gene transcript. 
Interestingly, the RVFV-NSs employs a different mechanism in preventing the serine 2 
phosphorylation. Unlike the BUNV-NSs, it directly targets the TFIIH kinase by interacting with 
its p44 subunit. This interaction prevents the assembly of the enzyme subunits to build a 
functional unit. The filamentous structures seen in the cell nucleus of cells transfected with 
the RVFV-NSs expression plasmid (see Figures 17 to 19) comprise of RVFV-NSs and some 
subunits of the TFIIH kinase including p44 (Le May et al. 2004). Such structures are not seen in 
the cell nucleus of the cells expressing the OROV-NSs. 
Experiments were carried out to look at the phosphorylation state of the RNAP II in the 
presence of NSs (see 3.1.2). The phosphorylation of serine 5 (initiation of transcription) and of 
serine 2 (elongation of transcript) of the hepta repeats of the CTD were looked at by 
incubating the cells with antibodies against the respective phosphorylated sites.  
The antibodies against phospho-serine 5 found their target in cells transfected with the OROV-
NSs expression plasmid (see Figure 18): there was no reduction in the phosphorylation of 
serine 5 meaning initiation of transcription by RNAP II was not affected. Interestingly, there 
was also no weakening of fluorescence signal in the presence of OROV-NSs when antibodies 
against phosphor-serine 2 were used, in contrast to the results obtained for the BUNV- and 
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RVFV-NSs (see above). The RNAP II is therefore “switched on” by the cell and it should be able 
to initiate transcription and elongate the transcript. Close inspection of the confocal 
microscope images revealed, that most of the cells that express the OROV-NSs have a very 
distinct distribution of the RNAP II in comparison to the control. When OROV-NSs is present, 
active RNAP II (= phosphorylated at serine 2 and 5, Figures 17 and 18) seems to reorganize 
itself in the cell nucleus into regions of high polymerase amount. In the control, the active 
RNAP II is distributed over the entire cell nucleus rather equally (see Figure 19). This RNAP II 
reorganization also appears to only involve the active RNAP II (H5 and H14), since the regions 
of high fluorescence are not seen with the N20 antibody that targets both active and inactive 
RNAP II (see Figure 19). Some OROV-NSs protein positive cells however do not show this 
cluster phenomenon. This could mean that such an aggregation of active RNAP II is time 
(phase) dependent. On Figure 19, there is no weakening of the N20 signal to be seen in the 
presence of the OROV-NSs, suggesting that there is no RNAP II degradation induced by OROV-
NSs (fluorescence signal similar to that of the control).This means that the reduction in 
transcriptional activity induced by the OROV-NSs is not due to degradation of RNAP II. 
On close inspection, the OROV-NSs seems to form circular ring-like structures in the cell 
nucleus in contrast to the filamentous  structures formed when the RVFV-NSs protein 
associates with the p44 subunit of the TFIIH kinase.    
All results taken together, the OROV-NSs protein seems to inhibit transcriptional activity using 
another strategy other than that of its relatives BUNV and RVFV.  
It is interesting that the OROV, RVFV and the BUNV would all inhibit general gene transcription 
of their host cells, because they themselves are directly dependent on the host cells mRNAs 
(Bouloy et al. 2001). The viral L proteins cut capped oligonucleotides off the 5’ end of the host 
cells mRNAs and the virus uses them as its own primers – this is an obligatory process for viral 
transcription (Elliott and Weber 2009). It is therefore interesting, why they inhibit general 
gene transcription, as this would seize their supply of new cellular mRNA. The close relative to 
the OROV, the LACV, has been examined from this perspective and it turns out that inhibiting 
the RNAP II with actinomycin D, does not suppress viral RNA synthesis (Raju and Kolakofsky 
1988). Apparently, full RNAP II activity is not that crucial for the viruses and the cytoplasmic 
pool of cellular mRNAs is sufficient for viral RNA synthesis and production of progeny viruses. 
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The general suppression of host cell gene expression is probably not only based on the 
activities of the NSs proteins, but also on the fact that the 5’ end, including the cap, of cellular 
mRNAs are stolen by the viral L protein. Without such a protective cap end, the cellular 
mRNAs are degraded by proteasomes within the cell (Raju and Kolakofsky 1988). 
Furthermore, inhibition of gene expression by Orthobunyaviruses is not observed in infected 
vector insect cells which seem to be persistently infected (Hacker et al. 1989), suggesting a 
specificity of inhibition to mammalian cells. The difference between insect and mammalian 
CTD of the RNAP II are 10 amino acids conserved only among vertebrates. These 10 amino 
acids have been found to be important in conjunction with the phosphorylated serines 5 and 2 
of the 52 repeats for efficient transcription (Fong et al. 2003). 
 
4.2 The OROV Minireplicon System 
Minireplicons are very important tools for understanding viral transcription and 
replication.They allow studying these processes in the absence of infectious virus. They consist 
of expression plasmids for the viral polymerase and the viral nucleoprotein and a minigenome. 
The minigenome mimicks a viral genomic segment (reporter gene flanked by viral NTRs) and 
can only be transcribed by the viral polymerase. Recently, an attempt was made to establish a 
minireplicon for OROV (Keisers). This system was however inactive: transfection of BSR-T7 
cells with the OROV minigenome plasmid together with the OROV nucleocapsid (N) and 
polymerase (L) expression plasmids did not lead to the expected renilla luciferase gene 
expression (see Figure 20 and 22). The aim here was to find the cause of the problem. 
Firstly, possible procedural errors had to be excluded by creating a LACV minireplicon parallel 
to that of the OROV. The LACV minigenome, -N and –L protein expression plasmids were 
transfected exactly the same way the OROV expression plasmids were. The LACV minireplicon 
system resulted in high renilla luciferase activity (see Figure 20 and 22). Therefore, the 
problem was apparently not a methodical one. 
Experiments were then carried out to indirectly examine the functionality of the OROV 
minigenome. For this, the LACV-L and –N protein expression plasmids were co-transfected 
together with the OROV minigenome expression plasmid (see Figure 20/B). The LACV 
polymerase (L) and nucleoprotein (N) apparently recognized the OROV minigenome. The 
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renilla luciferase activity was a lot higher than that of the negative control (although not as 
high as when only LACV components were present; see Figure 20/A). The NTRs of 
Orthobunyaviruses being quite conserved could at least in part explain the recognition of the 
OROV minigenome by the LACV components.  
The OROV-L and –N protein expression plasmids were then both individually examined for 
functionality by co-transfecting them respectively with the other components of the LACV. 
Transfection with the OROV-L and/or –N protein expression plasmids together with 
components of the LACV minireplicon (see Figure 22) was unable to induce significant renilla 
luciferase gene expression. 
It was therefore assumed that either the OROV-L or –N was dysfunctional. The OROV-N and –L 
expression plasmids were sequenced in search of mutations. The N expression plasmid 
sequence was correct. There were however six mutations (see 3.2) in the OROV polymerase 
gene (L), when compared to the L segment sequence of the OROV in the NCBI gene bank. 
These six mutations (insertions) would mean the addition of two amino acids in the L protein, 
which could very well lead to a dysfunctional OROV polymerase. This mutated sequence of the 
OROV polymerase gene was then compared to the sequences of the other Orthobunyaviruses. 
It turned out that the other Orthobunyaviruses have the same mutated sequence. It appears 
to be a highly conserved sequence amongst the Orthobunyaviruses (Keisers). The published 
reference sequence for the OROV polymerase is therefore probably wrong. Hence, it is 
possible that these mutations have no negative influence on the functionality of the OROV 
polymerase. 
Each segment of the OROV genome has a promoter region that is not translated (NTR). The 5’ 
NTR of a particular segment is partially complementary to the 3’ NTR of the same segment. 
That is why each of the three OROV segment tend to form a panhandle structure. These 
regions were initially not sequenced during the research of this thesis.   
The ORF of the OROV minigenome was sequenced and found to be correct. After conclusion of 
this thesis, it was found that both NTR sequences of the minireplicon were correct in 
comparison to the international gene bank. The published NTR sequence however differs from 
those of the other Orthobunyviruses in one nucleotide, although this region is otherwise 
highly conserved (Keisers). This different nucleotide would form an additional bond eventually 
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affecting the activity of the viral polymerase. The reference sequence used to create the OROV 
minigenome could therefore be wrong. Therefore, the sequence of the NTRs has to be 
experimentally confirmed. A possible approach involves isolation of viral RNA from virus 
particles instead of infected cells. In contrast to RNA from cells, which represent a mixture of 
viral and cellular mRNAs and viral genome segments, RNA from viral particles contains only 
genome segments. Subsequent 5’ and 3’ RACE-RT-PCR using this viral genomic RNA will 
recover the NTRs, which can then be sequenced. 
Getting this minireplicon system to work is empirical. An interesting breakthrough in the 
prevention of Bunyaviridae infections using a reverse genetics system has been described for 
the LACV (Blakqori and Weber 2005). The LACV was completely artificially assembled. For this, 
the M segment of the virus was also cloned and transfected into a cell line in addition to the 
other minireplicon components (see above). This recombinant LACV was based on cDNA that 
was mutated on the S segment and expressed the N protein but not the NSs protein. When 
mice were infected with this recombinant virus that lacks its major virulence factor, they 
generated a protective immunity strong enough to prevent the infection by the wild type 
LACV. 
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5 Summary 
The OROV is a RNA virus that has a segmented, single stranded genome of negative polarity. It 
belongs to the Bunyaviridae family. Infection by the OROV causes an acute very debilitating 
febrile episode. This RNA virus is responsible for multiple and massive epidemic outbreaks in 
South America involving hundreds of thousands of infected people.  
The viruses of this family express a NSs protein as their major virulence factor, which inhibits 
the expression of IFN-β. IFN-β is a critical antiviral protein, whose expression, if inhibited, 
allows for the replication of virus particles. The experiments carried out in this thesis aim at 
characterizing the pathogenic mechanism of the NSs protein of the OROV.  
There are three transcriptional factors that are necessary for IFN-β gene expression and they 
are activated after viral recognition: IRF-3, NF-κB and AP-1.  
The OROV-NSs protein blocks the activation of the IFN-β promoter as well as the activation of 
the artificial IRF-3-, NF-κB- and AP-1-responsive promoters, and the constitutively active SV40 
promoter. The inhibitory effect of the OROV-NSs does not lie in translation inhibition since 
mRNA can still be translated to protein in the presence of the NSs protein, irrespective of the 
cap-/IRES-status of the mRNA. Instead, the OROV-NSs inhibits IFN-β gene transcription 
probably by inhibiton of the RNAP II. A T7 polymerase based expression system can bypass the 
NSs inhibitory effect, showing certain specificity for inhibition of transcription mediated by 
mammalian RNAP II. 
In contrast to the NSs of its close relatives, BUNV and RVFV, the OROV-NSs does not influence 
the phosphorylation of the serine 2 (elongation and 3’-end processing) of the heptapeptide 
repeat at the CTD of the RNAP II. The OROV-NSs also does not prevent the phosphorylation of 
serine 5. Its transcription inhibitory effect is not due to the induction of degradation of the 
RNAP II. 
The OROV-NSs induces a reorganization of active RNAP II in the nucleus of some cells and is 
probably associated with the RNAP II-containing transcription complex. 
The second part of this thesis involved setting up a functional minireplicon system for the 
OROV, as this has never been done before. A minireplicon system is critical in understanding a 
viruses transcription and replication processes. Experiments carried out, showed that the 
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functional OROV minireplicon system could not be established probably due to sequence 
errors either in the OROV-L ORF or in the NTRs of the OROV minigenome, which were present 
in the expression constructs due to the faulty OROV reference sequences in the international 
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